2024/12/12 更新

お知らせ

 

写真a

ミモリ コオシ
三森 功士
MIMORI KOSHI
所属
九州大学病院別府病院 外科 教授
職名
教授
電話番号
0977271645
プロフィール
当教室では『真実はプリミティブなものにあり、様々な生物はフラクタルな関係性にあり」という基本的構想のもと、発がんから癌進展・再発にいたるまでの過程を『生物の進化論』に準えて真の機序解明に取り組んでいる。また、臨床的には『がん患者の生命予後の大幅な延長』ならびに『様々な臨床の局面における患者個別のあるいは疾患包括的な課題の解決』を目標として、基礎研究(ドライ解析とウェット解析)の知識と技術を高めつつ臨床における課題解決を目指している。 ●固形がんにおける進化: 進行大腸がんにおいては、多くのドライバー変異はクローナルに存在していた(Uchi R. Takahashi Y., et al. PLoS Genet 2016)。一方、早期大腸がんの進化の過程についても同様なアプローチで解析したところ、ドライバー変異はサブクローナルに散在していた。早期がんに比べて進行がんにおいて有意にコピー数変異(染色体の増幅と欠失)が多かった(Saito T., Nat Commun 2018)。 われわれは食道発がんに関わる遺伝子多型ALDH2とADH1Bのリスクアリルを明らかにした(Tanaka F., GUT 2010)、体細胞変異については日本人食道がんの包括的遺伝子変異profileを明らかにした(Sawada G., 201)、さらに近年、京都大学教授小川誠司先生らが同データを用いて食道がんの進化を明らかにする論文を報告された(Yokoyama A., Ogawa S., et al, Nature 2019)。 さらに、肝内胆管がん、膵がん、乳がんに関しても、臨床的に有用な真の治療標的を探索することを目的として進化解析研究を継続している。 ●新たな治療標的の同定:今日までのゲノム進化解析において固形癌は極めて重要なドライバー変異が最初に突然変異をきたした後クローナルに進展し、コピー数変異を来して大きく進展することを改めて明らかにした。特にわれわれは大腸がんにおけるクローナルな増幅を来すゲノム領域として7番染色体に局在する変異遺伝子に注目している。特にゲノム増幅する領域のなかで、新たな大腸癌発癌メカニズムとしての“タンパク翻訳開始点制御の異常”をきたす遺伝子5MP1 を見いだした(Sato K, EBioMed 2019)。また、転写機構を制御するDDX56遺伝子の臨床的意義をあきらかにした(Kouyama Y, Cancer Sci 2019)。さらに、 ●リポジショニング薬の開発:SK-818は、株式会社三和化学から1996年より医薬品として承認されている慢性B型肝炎治療薬であり、20年来の使用経験から安全性がある程度担保されているだけでなくドラッグリポジショニング(安価な薬剤の適応疾患の拡大)の観点から医療経済的にも良好である。昨年度末で無事に安全性試験を終えている。現在、SK818が単剤でも有効性を示すことより、その作用機序の解明を目指している。また他の様々な癌腫における候補薬同定にも鋭意取り組んでいる。 ●リキッドバイオプシー (1)消化器がんの血液中で検出されるctDNAの特徴: ctDNA変異が検出されるクローンの特徴は明らかではない。大腸がんは原発巣から再発を来すまでの過程において、転移再発を決める選択圧のひとつとして腫瘍免疫の関与が考えられる。がん再発時にctDNAで変異が検出されるクローンの特徴について腫瘍免疫応答の視点から明らかにする基礎的研究を行っている。 (2)慢性炎症と胃癌:上部消化管内視鏡検査により、胃粘膜の萎縮の広がりを分類した「木村・竹本分類」という分類法があり、この分類法は、Close(C)とOpen(O)の各々1-3段階で萎縮の程度を示しており、C-1からO-3になるほど萎縮が進行した前癌状態と考えられ胃癌のリスクが高いとされている。われわれは胃前がん病変を有する症例の血清中に存在するmicroRNAを同定した。 6)おもな共同研究 代表研究 AMED次世代がん医療創生研究事業 研究開発課題名:難治がん特異的エピゲノム変異を標的にしたctDNA検出法の確立  がんゲノム医療がはじまり固形癌の変異情報に基づいた治療法の推奨が開始された。しかし、膵がん、胆管がん、大腸がん再発など難治性がんについては固形癌へのアクセスが困難なことが多い。したがって、がん種特異性が高く、低侵襲、低コストで実装性の高いリキッドバイオプシー(LB)の確立が急務である。われわれはこれら3つの難治がんを対象にctDNA上の、がん種特異的エピゲノム変異に注目し検出の有用性を明らかにする。またLBの最大の特徴は担がん量を経時的にモニタリングできる点であり、本研究では大腸がん再発症例をモデルとしてその臨床的意義を明らかにする。 分担研究 (1)PRISM 【代表者】九州工業大学・教授 山西芳裕先生 研究開発課題名:創薬標的分子の確かしさを検証するツール物質の探索 医薬ビッグデータに基づいて、対象疾患の創薬標的候補の「確からしさ」の検証実験に利用可能なツール化合物を探索するインシリコ手法を開発する。 分担研究開発課題名:Gefitinib抵抗性肺がんに対する分子標的薬の同定と実験による検証。 (2)AMED革新的がん医療実用化研究事業: 【代表者】国立研究開発法人国立がん研究センター研究所 がんゲノミクス研究分野 分野長 柴田龍弘先生 研究開発課題名:国際共同研究に資する大規模日本人がんゲノム・オミックス・臨床データ統合解析とゲノム医療推進に向けた知識基盤構築 分担研究課題名:ゲノム新技術を導入した日本人がんゲノミクスデータベース構築・データ共有  特に、われわれは、肝内胆管癌におけるオミックス進化機構の解明と進化の選択圧としての腫瘍免疫応答あるいは代謝産物についての研究を鋭意推進中。 (3)AMED革新的がん医療実用化研究事業 【代表者】金沢大学がん進展制御研究所 教授 大島正伸先生 研究開発課題名:大腸がん微小転移巣形成機構の理解による新規予防治療戦略の確立 1.微小転移巣における線維性ニッチの役割の解明 2.HSCおよびKupffer細胞の関与の解明 3. がん細胞とHSCの相互作用の解明 4. 候補遺伝子の探索と検証 5. ヒト大腸がん細胞における検証
ホームページ
外部リンク

学位

  • 医学博士

研究テーマ・研究キーワード

  • 研究テーマ:膵臓癌の新規治療標的の同定。特にエンハンサープロモーターにおける遺伝子発現制御領域に注目して

    研究キーワード:全ゲノムシーケンス

    研究期間: 2022年8月

  • 研究テーマ:リキッドバイオプシー計画

    研究キーワード:リキッドバイオプシー

    研究期間: 2019年4月 - 2023年3月

  • 研究テーマ:根治手術可能な乳がん患者に対する SK-818 の安全性評価のための医師主導治験

    研究キーワード:医師主導治験、SK-818、ドラッグリポジショニング

    研究期間: 2018年6月

  • 研究テーマ:原発巣から転移巣への進化

    研究キーワード:全エキソーム、RNAseq、TCRレパトア

    研究期間: 2018年6月

  • 研究テーマ:大腸がんの進化についての研究

    研究キーワード:進化、大腸がん

    研究期間: 2018年6月

  • 研究テーマ:遺伝性消化器腫瘍のゲノム解析

    研究キーワード:Lynch症候群大腸がん症例、多遺伝子パネル解析

    研究期間: 2017年4月 - 2019年3月

受賞

  • 2021年度鶴尾隆賞

    2022年6月   日本がん分子標的治療学会  

  • 日本消化器外科学会賞「JSGS Science of the Year 2017 (学術部門)」

    2017年6月   日本消化器外科学会  

  • 平成26年度 大原 毅 賞受賞

    2015年6月   日本消化器癌発生学会   消化器癌におけるゲノム・エピゲノムレベルにおける進化の解明と難治性を生む多様性の克服

  • 九州大学研究活動表彰受賞

    2012年11月   九州大学  

  • 平成23年度「日本医師会医学研究奨励賞」

    2011年9月   日本医師会  

  • 九州大学研究活動表彰受賞

    2010年11月   九州大学生体防御医学研究所  

  • 公益信託 外科学研究助成基金

    2009年9月   外科学会   マイクロRNAを介した癌転移機構解明に関するシンポジウムおよび技術指導

  • 第18回日本消化器癌発生学会 最優秀賞

    2007年11月   日本消化器癌発生学会   【課題名】消化器癌における炎症発癌機構と癌抑制遺伝子FHITとの関係

  • かなえ研究奨励賞

    2007年9月  

  • 平成19年度第1回海外派遣事業(助成)

    2007年2月   がん特定領域国際交流委員会  

  • 平成18年度文部科学大臣表彰若手科学者賞

    2006年3月   文部科学省   癌抑制遺伝子FHITの臨床応用に関する研究

  • 日本膵臓病学会研究奨励賞

    2005年1月   日本膵臓病学会  

  • 日本癌学会研究奨励賞

    2004年10月   日本癌学会  

  • 日本がん転移学会研究奨励賞

    2004年7月   日本がん転移学会  

  • 国際トラベルグラント賞(助成)

    2003年10月   九州大学  

  • 第12回日本がん転移学会 優秀演題賞

    2003年6月   日本がん転移学会  

  • 上原記念研究助成

    2002年9月   上原記念研究   研究助成

  • かなえ研究奨励賞

    2002年9月  

▼全件表示

論文

  • Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis

    Koshi Mimori

    Cancer Res   73 ( 7 )   2013年4月

     詳細を見る

    記述言語:英語  

  • MicroRNA-125a-5p is an independent prognostic factor in gastric cancer,and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. 査読 国際誌

    Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Mori M.

    Clin Cancer Res.   17 ( 9 )   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • MicroRNA-125a-5p is an independent prognostic factor in gastric cancer,and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. 査読 国際誌

    Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Mori M.

    Clin Cancer Res.   17 ( 9 )   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • FHIT Suppresses Inflammatory Carcinogenic Activity by Inducing Apoptosis in Esophageal Epithelial Cells. 査読 国際誌

    Mimori K, Yokobori T, Iwatsuki M, Sudo T, Tanaka F, Shibata K, Ishii H,Mori M

    J Nucleic Acid Invest   2010年5月

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

  • Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. 査読 国際誌

    Mimori K, Druck T, Inoue H, Hansjuerg A, Berk L, Mori M, Huebner K, Croce CM.

    Proc Natl Acad Sci (USA)   96 ( 13 )   7456 - 7461   1999年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1073/pnas.96.13.7456

  • Cancer-specific chromosome alterations in the constitutive fragile region FRA3B.

    Mimori K, Druck T, Inoue H, Alder H, Berk L, Mori M, Huebner K and Croce CM

    Proc Natl Acad Sci (U.S.A)   96 ( 13 )   7456 - 7461   1999年6月

     詳細を見る

    記述言語:英語  

    DOI: 10.1073/pnas.96.13.7456

  • <i>SHARPIN</i> is a novel gene of colorectal cancer that promotes tumor growth potentially via inhibition of p53 expression

    Nakano, Y; Masuda, T; Sakamoto, T; Tanaka, N; Tobo, T; Hashimoto, M; Tatsumi, T; Saito, H; Takahashi, J; Koike, K; Abe, T; Ando, Y; Ozato, Y; Hosoda, K; Hirose, K; Higuchi, S; Ikehara, T; Hisamatsu, Y; Toshima, T; Yonemura, Y; Ogino, T; Uemura, M; Eguchi, H; Doki, Y; Mimori, K

    INTERNATIONAL JOURNAL OF ONCOLOGY   65 ( 6 )   2024年12月   ISSN:1019-6439 eISSN:1791-2423

     詳細を見る

  • Interview with Prof. Dr. Jeffrey Drebin, President of the 2024 President Elect of the American Surgical Association

    Mimori, K; Fujii, T; Sho, M; Endo, I; Shirabe, K; Kitagawa, Y

    ANNALS OF GASTROENTEROLOGICAL SURGERY   2024年11月   ISSN:2475-0328

     詳細を見る

  • Esophageal lymphangioma: Endoscopic ultrasound, computed tomography, and magnetic resonance imaging appearance.

    Nanjo K, Tsurumaru D, Hirakawa M, Nishimuta Y, Mimori K, Ishigami K

    Radiology case reports   19 ( 11 )   4841 - 4844   2024年11月   ISSN:1930-0433

     詳細を見る

    記述言語:英語  

    DOI: 10.1016/j.radcr.2024.07.144

    PubMed

  • What Are Risk Factors for Graft Loss in Patients Who Underwent Simultaneous Splenectomy During Living-donor Liver Transplantation?

    Toshima, T; Harada, N; Itoh, S; Tomiyama, T; Toshida, K; Morita, K; Nagao, Y; Kurihara, T; Tomino, T; Kosai-Fujimoto, Y; Mimori, K; Yoshizumi, T

    TRANSPLANTATION   108 ( 7 )   1593 - 1604   2024年7月   ISSN:0041-1337 eISSN:1534-6080

     詳細を見る

    記述言語:英語   出版者・発行元:Transplantation  

    Background. The consensus that portal venous pressure modulation, including splenectomy (Spx), prevents portal hypertension-related complications after living-donor liver transplantation (LDLT) has been established. However, little evidence about the risk factors for graft loss after simultaneous Spx during LDLT is available. This study aimed to identify the independent predictors of graft loss after simultaneous Spx during LDLT. Methods. Data of 655 recipients who underwent LDLT between 1997 and 2021 were collected and separated into the simultaneous Spx group (n=461) and no-Spx group (n=194). Results. The simultaneous Spx group had significantly lower serum total bilirubin levels, drained ascites volumes, and prothrombin time-international normalized ratios on postoperative day 14 than the no-Spx group (P<0.001 for each). Incidences of small-for-size graft syndrome (P<0.001), acute cellular rejection (P=0.002), and sepsis (P=0.007) were significantly lower in the Spx group. Graft survival of the Spx group was significantly better than that of the no-Spx group (P<0.001; hazard ratio [HR], 1.788; 95% confidence interval, 1.214-2.431). A multivariate analysis revealed that 3 variables, platelet count ≤4.0×104/mm3 (P=0.029; HR, 2.873), donor age ≥60 y old (P=0.013; HR, 6.693), and portal venous pressure at closure ≥20 mm Hg (P=0.010; HR, 3.891), were independent predictors of graft loss within 6 mo after simultaneous Spx during LDLT. Conclusions. Spx is a safe inflow modulation procedure with a positive impact on both postoperative complications and prognosis for most patients. However, patients with the 3 aforementioned independent factors could experience graft loss after LDLT.

    DOI: 10.1097/TP.0000000000004952

    Web of Science

    Scopus

    PubMed

  • Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer(タイトル和訳中)

    Hashimoto Masahiro, Masuda Takaaki, Nakano Yusuke, Tobo Taro, Saito Hideyuki, Koike Kensuke, Takahashi Junichi, Abe Tadashi, Ando Yuki, Ozato Yuki, Hosoda Kiyotaka, Higuchi Satoshi, Hisamatsu Yuichi, Toshima Takeo, Yonemura Yusuke, Hata Tsuyoshi, Uemura Mamoru, Eguchi Hidetoshi, Doki Yuichiro, Mori Masaki, Mimori Koshi

    Cancer Science   115 ( 6 )   1866 - 1880   2024年6月   ISSN:1347-9032

     詳細を見る

    記述言語:英語   出版者・発行元:John Wiley & Sons Australia, Ltd  

  • Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer

    Hashimoto, M; Masuda, T; Nakano, Y; Tobo, T; Saito, H; Koike, K; Takahashi, J; Abe, T; Ando, Y; Ozato, Y; Hosoda, K; Higuchi, S; Hisamatsu, Y; Toshima, T; Yonemura, Y; Hata, T; Uemura, M; Eguchi, H; Doki, Y; Mori, M; Mimori, K

    CANCER SCIENCE   115 ( 6 )   1866 - 1880   2024年6月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Science  

    Bromodomain and extraterminal domain (BET) family proteins are epigenetic master regulators of gene expression via recognition of acetylated histones and recruitment of transcription factors and co-activators to chromatin. Hence, BET family proteins have emerged as promising therapeutic targets in cancer. In this study, we examined the functional role of bromodomain containing 3 (BRD3), a BET family protein, in colorectal cancer (CRC). In vitro and vivo analyses using BRD3-knockdown or BRD3-overexpressing CRC cells showed that BRD3 suppressed tumor growth and cell cycle G1/S transition and induced p21 expression. Clinical analysis of CRC datasets from our hospital or The Cancer Genome Atlas revealed that BET family genes, including BRD3, were overexpressed in tumor tissues. In immunohistochemical analyses, BRD3 was observed mainly in the nucleus of CRC cells. According to single-cell RNA sequencing in untreated CRC tissues, BRD3 was highly expressed in malignant epithelial cells, and cell cycle checkpoint-related pathways were enriched in the epithelial cells with high BRD3 expression. Spatial transcriptomic and single-cell RNA sequencing analyses of CRC tissues showed that BRD3 expression was positively associated with high p21 expression. Furthermore, overexpression of BRD3 combined with knockdown of, a driver gene in the BRD family, showed strong inhibition of CRC cells in vitro. In conclusion, we demonstrated a novel tumor suppressive role of BRD3 that inhibits tumor growth by cell cycle inhibition in part via induction of p21 expression. BRD3 activation might be a novel therapeutic approach for CRC.

    DOI: 10.1111/cas.16129

    Web of Science

    Scopus

    PubMed

  • Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer(タイトル和訳中)

    Nakano Takafumi, Takao Seiichiro, Dairaku Katsushi, Uno Naoki, Low Siew-Kee(Amanda), Hashimoto Masahiro, Tsuda Yasuo, Hisamatsu Yuichi, Toshima Takeo, Yonemura Yusuke, Masuda Takaaki, Eto Ken, Ikegami Toru, Fukunaga Yosuke, Niida Atsushi, Nagayama Satoshi, Mimori Koshi

    Cancer Science   115 ( 6 )   1989 - 2001   2024年6月   ISSN:1347-9032

     詳細を見る

    記述言語:英語   出版者・発行元:John Wiley & Sons Australia, Ltd  

  • Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer

    Nakano, T; Takao, S; Dairaku, K; Uno, N; Low, SK; Hashimoto, M; Tsuda, Y; Hisamatsu, Y; Toshima, T; Yonemura, Y; Masuda, T; Eto, K; Ikegami, T; Fukunaga, Y; Niida, A; Nagayama, S; Mimori, K

    CANCER SCIENCE   115 ( 6 )   1989 - 2001   2024年6月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Science  

    Considering the cost and invasiveness of monitoring postoperative minimal residual disease (MRD) of colorectal cancer (CRC) after adjuvant chemoradiotherapy (ACT), we developed a favorable approach based on methylated circulating tumor DNA to detect MRD after radical resection. Analyzing the public database, we identified the methylated promoter regions of the genes FGD5, GPC6, and MSC. Using digital polymerase chain reaction (dPCR), we termed the “amplicon of methylated sites using a specific enzyme” assay as “AMUSE.” We examined 180 and 114 pre- and postoperative serial plasma samples from 28 recurrent and 19 recurrence-free pathological stage III CRC patients, respectively. The results showed 22 AMUSE-positive of 28 recurrent patients (sensitivity, 78.6%) and 17 AMUSE-negative of 19 recurrence-free patients (specificity, 89.5%). AMUSE predicted recurrence 208 days before conventional diagnosis using radiological imaging. Regarding ACT evaluation by the reactive response, 19 AMUSE-positive patients during their second or third blood samples showed a significantly poorer prognosis than the other patients (p = 9E-04). The AMUSE assay stratified four groups by the altered patterns of tumor burden postoperatively. Interestingly, only 34.8% of cases tested AMUSE-negative during ACT treatment, indicating eligibility for ACT. The AMUSE assay addresses the clinical need for accurate MRD monitoring with universal applicability, minimal invasiveness, and cost-effectiveness, thereby enabling the timely detection of recurrences. This assay can effectively evaluate the efficacy of ACT in patients with stage III CRC following curative resection. Our study strongly recommends reevaluating the clinical application of ACT using the AMUSE assay.

    DOI: 10.1111/cas.16149

    Web of Science

    Scopus

    PubMed

  • Case report:A rare case of triple negative breast cancer with development of acute pancreatitis due to dexamethasone during adjuvant chemotherapy. 査読 国際誌

    Ohmura H, Tobo T, Ando Y, Masuda T, Mimori K, Akashi K, Baba E.

    Front Oncol.   14   1340419 - 1340419   2024年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3389/fonc.2024.1340419.

  • A comprehensive summary of the impact of the COVID era on various gastrointestinal cancers

    Mimori, K

    ANNALS OF GASTROENTEROLOGICAL SURGERY   8 ( 3 )   372 - 373   2024年5月   ISSN:2475-0328

     詳細を見る

    記述言語:英語   出版者・発行元:Annals of Gastroenterological Surgery  

    DOI: 10.1002/ags3.12811

    Web of Science

    Scopus

    PubMed

  • Spatial and single-cell colocalisation analysis reveals MDK-mediated immunosuppressive environment with regulatory T cells in colorectal carcinogenesis

    Hashimoto, M; Kojima, Y; Sakamoto, T; Ozato, Y; Nakano, Y; Abe, T; Hosoda, K; Saito, H; Higuchi, S; Hisamatsu, Y; Toshima, T; Yonemura, Y; Masuda, T; Hata, T; Nagayama, S; Kagawa, K; Goto, Y; Utou, M; Gamachi, A; Imamura, K; Kuze, Y; Zenkoh, J; Suzuki, A; Takahashi, K; Niida, A; Hirose, H; Hayashi, S; Koseki, J; Fukuchi, S; Murakami, K; Yoshizumi, T; Kadomatsu, K; Tobo, T; Oda, Y; Uemura, M; Eguchi, H; Doki, Y; Mori, M; Oshima, M; Shibata, T; Suzuki, Y; Shimamura, T; Mimori, K

    EBIOMEDICINE   103   105102   2024年5月   ISSN:2352-3964

     詳細を見る

    記述言語:英語   出版者・発行元:eBioMedicine  

    Background: Cell–cell interaction factors that facilitate the progression of adenoma to sporadic colorectal cancer (CRC) remain unclear, thereby hindering patient survival. Methods: We performed spatial transcriptomics on five early CRC cases, which included adenoma and carcinoma, and one advanced CRC. To elucidate cell–cell interactions within the tumour microenvironment (TME), we investigated the colocalisation network at single-cell resolution using a deep generative model for colocalisation analysis, combined with a single-cell transcriptome, and assessed the clinical significance in CRC patients. Findings: CRC cells colocalised with regulatory T cells (Tregs) at the adenoma–carcinoma interface. At early-stage carcinogenesis, cell–cell interaction inference between colocalised adenoma and cancer epithelial cells and Tregs based on the spatial distribution of single cells highlighted midkine (MDK) as a prominent signalling molecule sent from tumour epithelial cells to Tregs. Interaction between MDK-high CRC cells and SPP1+ macrophages and stromal cells proved to be the mechanism underlying immunosuppression in the TME. Additionally, we identified syndecan4 (SDC4) as a receptor for MDK associated with Treg colocalisation. Finally, clinical analysis using CRC datasets indicated that increased MDK/SDC4 levels correlated with poor overall survival in CRC patients. Interpretation: MDK is involved in the immune tolerance shown by Tregs to tumour growth. MDK-mediated formation of the TME could be a potential target for early diagnosis and treatment of CRC. Funding: Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Science Research; OITA Cancer Research Foundation; AMED under Grant Number; Japan Science and Technology Agency (JST); Takeda Science Foundation; The Princess Takamatsu Cancer Research Fund.

    DOI: 10.1016/j.ebiom.2024.105102

    Web of Science

    Scopus

    PubMed

  • アルコールなどのリスク因子による食道発がん機構の総合的な理解

    三森 功士

    日本気管食道科学会会報   75 ( 2 )   67 - 68   2024年4月   ISSN:00290645 eISSN:18806848

     詳細を見る

    記述言語:日本語   出版者・発行元:特定非営利活動法人 日本気管食道科学会  

    DOI: 10.2468/jbes.75.67

    CiNii Research

  • Field experiment of a telesurgery system using a surgical robot with haptic feedback. 査読 国際誌

    Ota M, Oki E, Nakanoko T, Tanaka Y, Toyota S, Hu Q, Nakaji Y, Nakanishi R, Ando K, Kimura Y, Hisamatsu Y, Mimori K, Takahashi Y, Morohashi H, Kanno T, Tadano K, Kawashima K, Takano H, Ebihara Y, Shiota M, Inokuchi J, Eto M, Yoshizumi T, Hakamada K, Hirano S, Mori M.

    Surg Today.   54 ( (4) )   375 - 381   2024年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00595-023-02732-7.

  • Spatial and single-cell colocalisation analysis reveals MDK-mediated immunosuppressive environment with regulatory T cells in colorectal carcinogenesis. 査読 国際誌

    Hashimoto M, Kojima Y, Sakamoto T, Ozato Y, Nakano Y, Abe T, Hosoda K, Saito H, Higuchi S, Hisamatsu Y, Toshima T, Yonemura Y, Masuda T, Hata T, Nagayama S, Kagawa K, Goto Y, Utou M, Gamachi A, Imamura K, Kuze Y, Zenkoh J, Suzuki A, Takahashi K, Niida A, Hirose H, Hayashi S, Koseki J, Fukuchi S, Murakami K, Yoshizumi T, Kadomatsu K, Tobo T, Oda Y, Uemura M, Eguchi H, Doki Y, Mori M, Oshima M, Shibata T, Suzuki Y, Shimamura T, Mimori K.

    105102. - 105102.   2024年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.ebiom.2024.105102.

  • 触覚フィードバック付き手術ロボットを用いた遠隔手術システムのフィールド実験(Field experiment of a telesurgery system using a surgical robot with haptic feedback)

    Ota Mitsuhiko, Oki Eiji, Nakanoko Tomonori, Tanaka Yasushi, Toyota Satoshi, Hu Qingjiang, Nakaji Yu, Nakanishi Ryota, Ando Koji, Kimura Yasue, Hisamatsu Yuichi, Mimori Koshi, Takahashi Yoshiya, Morohashi Hajime, Kanno Takahiro, Tadano Kotaro, Kawashima Kenji, Takano Hironobu, Ebihara Yuma, Shiota Masaki, Inokuchi Junichi, Eto Masatoshi, Yoshizumi Tomoharu, Hakamada Kenichi, Hirano Satoshi, Mori Masaki

    Surgery Today   54 ( 4 )   375 - 381   2024年4月   ISSN:0941-1291

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

    手術室と遠隔地にそれぞれ触覚フィードバック付きの術者用コンソールを設置し、遠隔手術における触覚フィードバックの有用性を検証し、さらに遠隔ロボット手術の安全性向上を目的として、動物実験を行った。術者用コンソールは福岡市と別府市の手術室に設置し、3段階の触覚フィードバックレベルをランダム順に設定した。術者(現地5名、遠隔地5名)を盲検化し、各触覚レベルでロボット鉗子によりブタの腸を把持する、持ち上げる、下げる、離すという一連の動作を10回繰り返してもらった。その結果、課題の精度や平均把持力には、術者の場所による顕著な差は見られなかった。しかし、遠隔地の場合は現地よりも平均課題完了時間が有意に長く、system usability scaleが有意に低かった。触覚フィードバックレベル間で、課題の精度や課題完了時間に顕著な差はなかったが、触覚フィードバックがある場合はない場合よりも有意に弱い力で臓器を把持することができた。さらに、触覚フィードバックがある場合、ロボット手術の経験が豊富な外科医は、経験の浅い外科医よりも弱い把持力で同等のタスクを行う傾向があった。

  • Field experiment of a telesurgery system using a surgical robot with haptic feedback

    Ota, M; Oki, E; Nakanoko, T; Tanaka, Y; Toyota, S; Hu, QJ; Nakaji, Y; Nakanishi, R; Ando, K; Kimura, Y; Hisamatsu, Y; Mimori, K; Takahashi, Y; Morohashi, H; Kanno, T; Tadano, K; Kawashima, K; Takano, H; Ebihara, Y; Shiota, M; Inokuchi, J; Eto, M; Yoshizumi, T; Hakamada, K; Hirano, S; Mori, M

    SURGERY TODAY   54 ( 4 )   375 - 381   2024年4月   ISSN:0941-1291 eISSN:1436-2813

     詳細を見る

    記述言語:英語   出版者・発行元:Surgery Today  

    Purpose: To verify the usefulness of haptic feedback in telesurgery and improve the safety of telerobotic surgery. Methods: The surgeon's console was installed at two sites (Fukuoka and Beppu; 140 km apart), and the patient cart was installed in Fukuoka. During the experiment, the surgeon was blinded to the haptic feedback levels and asked to grasp the intestinal tract in an animal model. The surgeon then performed the tasks at each location. Results: No marked differences in task accuracy or average grasping force were observed between the surgeon locations. However, the average task completion time was significantly longer, and the system usability scale (SUS) was significantly lower rating for remote operations than for local ones. No marked differences in task accuracy or task completion time were observed between the haptic feedback levels. However, with haptic feedback, the organ was grasped with a significantly weaker force than that without it. Furthermore, with haptic feedback, experienced surgeons in robotic surgery tended to perform an equivalent task with weaker grasping forces than inexperienced surgeons. Conclusion: The haptic feedback function is a tool that allows the surgeon to perform surgery with an appropriate grasping force, both on site and remotely. Improved safety is necessary in telesurgery; haptic feedback will thus be an essential technology in robotic telesurgery going forward.

    DOI: 10.1007/s00595-023-02732-7

    Web of Science

    Scopus

    PubMed

  • Liquid biopsy for breast cancer and other solid tumors: a review of recent advances

    Ohmura, H; Hanamura, F; Okumura, Y; Ando, Y; Masuda, T; Mimori, K; Akashi, K; Baba, E

    BREAST CANCER   2024年3月   ISSN:1340-6868 eISSN:1880-4233

     詳細を見る

    記述言語:英語   出版者・発行元:Breast Cancer  

    Liquid biopsy using circulating tumor DNA (ctDNA) has been reported to be less invasive and effective for comprehensive genetic analysis of heterogeneous solid tumors, including decision-making for therapeutic strategies, predicting recurrence, and detecting genetic factors related to treatment resistance in various types of cancers. Breast cancer, colorectal cancer, and lung cancer are among the most prevalent malignancies worldwide, and clinical studies of liquid biopsy for these cancers are ongoing. Liquid biopsy has been used as a companion diagnostic tool in clinical settings, and research findings have accumulated, especially in cases of colorectal cancer after curative resection and non-small cell lung cancer (NSCLC) after curative chemoradiotherapy, in which ctDNA detection helps predict eligibility for adjuvant chemotherapy. Liquid biopsy using ctDNA shows promise across a wide range of cancer types, including breast cancer, and its clinical applications are expected to expand further through ongoing research. In this article, studies on liquid biopsy in breast cancer, colorectal cancer, and NSCLC are compared focusing on ctDNA.

    DOI: 10.1007/s12282-024-01556-8

    Web of Science

    Scopus

    PubMed

  • Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer. 査読 国際誌

    Nakano T, Takao S, Dairaku K, Uno N, Low SA, Hashimoto M, Tsuda Y, Hisamatsu Y, Toshima T, Yonemura Y, Masuda T, Eto K, Ikegami T, Fukunaga Y, Niida A, Nagayama S, Mimori K.

    Cancer Sci.   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.16149.

  • Liquid biopsy for breast cancer and other solid tumors: a review of recent advances. 査読 国際誌

    Ohmura H, Hanamura F, Okumura Y, Ando Y, Masuda T, Mimori K, Akashi K, Baba E.

    Breast Cancer.   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12282-024-01556-8.

  • Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer. 査読 国際誌

    Hashimoto M, Masuda T, Nakano Y, Tobo T, Saito H, Koike K, Takahashi J, Abe T, Ando Y, Ozato Y, Hosoda K, Higuchi S, Hisamatsu Y, Toshima T, Yonemura Y, Hata T, Uemura M, Eguchi H, Doki Y, Mori M, Mimori K.

    Cancer Sci   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.16129.

  • The Future of Tele-Surgery in Japan

    MIMORI Koshi, OKI Eiji, YOSHIZUMI Tomoharu

    The Journal of The Japanese Society of Balneology, Climatology and Physical Medicine   87 ( 1 )   3 - 3   2024年2月   ISSN:00290343 eISSN:18843697

     詳細を見る

    記述言語:英語   出版者・発行元:The Japanese Society of Balneology, Climatology and Physical Medicine  

    DOI: 10.11390/onki.87_1.3

    CiNii Research

  • Case report: A rare case of triple negative breast cancer with development of acute pancreatitis due to dexamethasone during adjuvant chemotherapy

    Ohmura, H; Tobo, T; Ando, Y; Masuda, T; Mimori, K; Akashi, K; Baba, E

    FRONTIERS IN ONCOLOGY   14   1340419   2024年2月   ISSN:2234-943X

     詳細を見る

    記述言語:英語   出版者・発行元:Frontiers in Oncology  

    Here, we present the case of a 42-year-old female who developed acute pancreatitis due to dexamethasone during adjuvant chemotherapy for early triple negative breast cancer (TNBC). The patient received partial mastectomy and sentinel lymph node biopsy for early TNBC (cT1N0M0, cStage I) of the left breast. Dose-dense doxorubicin plus cyclophosphamide (ddAC) was administered as the adjuvant-chemotherapy; however, epigastralgia appeared on the fifth day of the first administration. A blood test showed a remarkable increase of serum pancreatic enzyme levels and computed tomography (CT) showed the swelling of pancreas and surrounding effusion, and she was diagnosed with moderate acute pancreatitis. As she had no history of excessive alcohol consumption or complication of cholelithiasis, dyslipidemia, or pancreatic neoplasm, drug-induced pancreatitis was suspected. Dexamethasone, which was administered as an antiemetic, was the suspected drug based on the drug administration history and previous report, and dexamethasone was discontinued from the second administration of ddAC. There was subsequently no recurrence of pancreatitis with no increase in serum pancreatic enzyme levels, and it was possible to complete adjuvant-chemotherapy. Alcohol, gallstones, dyslipidemia, and drugs have been reported as causes of pancreatitis; however, steroid-induced acute pancreatitis is extremely rare. We present the first case of acute pancreatitis induced by dexamethasone as the antiemetic.

    DOI: 10.3389/fonc.2024.1340419

    Web of Science

    Scopus

    PubMed

  • A rare case of liver regenerative and non-neoplastic lesion resembling a well-differentiated hepatocellular carcinoma

    Hirose, K; Toshima, T; Tobo, T; Kai, S; Hirakawa, M; Higuchi, S; Ofuchi, T; Hosoda, K; Yonemura, Y; Hisamatsu, Y; Masuda, T; Aishima, S; Mimori, K

    SURGICAL CASE REPORTS   10 ( 1 )   30   2024年2月   ISSN:2198-7793

     詳細を見る

  • A rare case of liver regenerative and non-neoplastic lesion resembling a well-differentiated hepatocellular carcinoma. 査読 国際誌

    Hirose K, Toshima T, Tobo T, Kai S, Hirakawa M, Higuchi S, Ofuchi T, Hosoda K, Yonemura Y, Hisamatsu Y, Masuda T, Aishima S, Mimori K.

    Surg Case Rep.   10 ( (1) )   30 - 30   2024年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s40792-024-01820-1.

  • What Are Risk Factors for Graft Loss in Patients Who Underwent Simultaneous Splenectomy During Living-donor Liver Transplantation? 査読 国際誌

    Toshima T, Harada N, Itoh S, Tomiyama T, Toshida K, Morita K, Nagao Y, Kurihara T, Tomino T, Kosai-Fujimoto Y, Mimori K, Yoshizumi T.

    Transplantation.   2024年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/TP.0000000000004952.

  • 高分化型肝細胞癌との鑑別に苦慮した肝再生性非腫瘍性病変の稀な1例(A rare case of liver regenerative and non-neoplastic lesion resembling a well-differentiated hepatocellular carcinoma)

    Hirose Kosuke, Toshima Takeo, Tobo Taro, Kai Satohiro, Hirakawa Masakazu, Higuchi Satoshi, Ofuchi Takashi, Hosoda Kiyotaka, Yonemura Yusuke, Hisamatsu Yuichi, Masuda Takaaki, Aishima Shinichi, Mimori Koshi

    Surgical Case Reports   10   1 of 6 - 6 of 6   2024年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Springer Berlin Heidelberg  

    49歳男性。特に既往や家族歴、飲酒歴、ウイルス感染歴などなかった。定期検診の腹部超音波検査で肝S7/8に2cm径の腫瘍および軽度の脂肪肝を伴う低エコー病変が認められた。単純CTでは高吸収域を示した。MRIでは、腫瘍はT1強調画像で境界部に高信号、内部に低信号を呈し、T2強調画像では低信号を示した。Gd-EOB-DTPA造影MRIでは、病変に脂肪が含まれており、EOB取り込みも認められた。以上より高分化型肝細胞癌(HCC)を疑い、腹腔鏡下S7/8部分切除術を施行した。患者は術後10日目に合併症なく退院した。病理組織検査の結果、過形成性病変や腺腫などの腫瘍性病変は認められず、肝小葉壊死を伴う再生性肝変化と診断した。

  • Third Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer: Summary of the results of a questionnaire survey of oncologists and diabetologists—Secondary publication

    Goto A., Ohashi K., Noda M., Noto H., Ueki K., Inoue M., Nishimura R., Takahashi S., Ioka T., Oshima M., Fujibayashi K., Tsuji A., Kodaira M., Tamakoshi A., Mimori K., Tanabe Y., Hara E., Matsuo K., Murakami Y., Watada H.

    Cancer Science   115 ( 2 )   672 - 681   2024年2月   ISSN:13479032

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Science  

    The Japan Diabetes Society and the Japan Cancer Association launched a joint committee and published their “First Joint Committee Report on Diabetes and Cancer” in 2013, compiling recommendations for physicians and health-care providers as well as for the general population. In 2016, the “Second Joint Committee Report on Diabetes and Cancer” summarized the current evidence on glycemic control and cancer risk in patients with diabetes. The current “Third Joint Committee Report on Diabetes and Cancer”, for which the joint committee also enlisted the assistance of the Japanese Society of Clinical Oncology and the Japanese Society of Medical Oncology, reports on the results from the questionnaire survey, “Diabetes Management in Patients Receiving Cancer Therapy,” which targeted oncologists responsible for cancer management and diabetologists in charge of glycemic control in cancer patients. The results of the current survey indicated that there is a general consensus among oncologists and diabetologists with regard to the need for guidelines on glycemic control goals, the relevance of glycemic control, and glycemic control during cancer therapy in cancer patients.

    DOI: 10.1111/cas.15975

    Scopus

    PubMed

  • Third Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on diabetes and cancer: summary of the results of a questionnaire survey of oncologists and diabetologists-secondary publication

    Goto, A; Ohashi, K; Noda, M; Noto, H; Ueki, K; Inoue, M; Nishimura, R; Takahashi, S; Ioka, T; Oshima, M; Fujibayashi, K; Tsuji, A; Kodaira, M; Tamakoshi, A; Mimori, K; Tanabe, Y; Hara, E; Matsuo, K; Murakami, Y; Watada, H

    DIABETOLOGY INTERNATIONAL   15 ( 1 )   1 - 4   2024年1月   ISSN:2190-1678 eISSN:2190-1686

     詳細を見る

    記述言語:英語   出版者・発行元:Diabetology International  

    The Japan Diabetes Society (JDS) and the Japan Cancer Association (JCA) launched a joint committee and published their “First Joint Committee Report on Diabetes and Cancer” in 2013, compiling recommendations for physicians and healthcare providers as well as for the general population. In 2016, the “Second Joint Committee Report on Diabetes and Cancer” summarized the current evidence on glycemic control and cancer risk in patients with diabetes. The current “Third Joint Committee Report on Diabetes and Cancer”, for which the joint committee also enlisted the assistance of the Japanese Society of Clinical Oncology (JSCO) and the Japanese Society of Medical Oncology (JSMO), reports on the results from the questionnaire survey, “Diabetes Management in Patients Receiving Cancer Therapy,” which targeted oncologists responsible for cancer management and diabetologists in charge of glycemic control in cancer patients. The results of the current survey demonstrated that there is a general consensus among oncologists and diabetologists with regard to the need for guidelines on glycemic control goals, the relevance of glycemic control, and glycemic control during cancer therapy in cancer patients.

    DOI: 10.1007/s13340-023-00672-8

    Web of Science

    Scopus

    PubMed

  • 大腸癌におけるepigenetic master regulator BRD3 発現の腫瘍進展における生物学的意義と、治療選択のバイオマーカーとしての可能性

    橋本 雅弘, 増田 隆明, 久松 雄一, 戸島 剛男, 米村 祐輔, 植村 守, 江口 英利, 土岐 祐一郎, 三森 功士

    日本分子腫瘍マーカー研究会誌   39 ( 0 )   18 - 19   2024年   eISSN:24338575

     詳細を見る

    記述言語:日本語   出版者・発行元:日本分子腫瘍マーカー研究会  

    DOI: 10.11241/jsmtmr.39.18

    CiNii Research

  • Real-time telementoring with 3D drawing annotation in robotic surgery. 査読 国際誌

    Nakanoko T, Oki E, Ota M, Ikenaga N, Hisamatsu Y, Toshima T, Kanno T, Tadano K, Kawashima K, Ohuchida K, Morohashi H, Ebihara Y, Mimori K, Nakamura M, Yoshizumi T, Hakamada K, Hirano S, Ikeda N, Mori M.

    Surg Endosc.   37 ( (12) )   9676 - 9683   2023年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00464-023-10521-z.

  • YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma

    Omori H., Nishio M., Masuda M., Miyachi Y., Ueda F., Nakano T., Sato K., Mimori K., Taguchi K., Hikasa H., Nishina H., Tashiro H., Kiyono T., Mak T.W., Nakao K., Nakagawa T., Maehama T., Suzuki A.

    Science Advances   9 ( 50 )   2023年12月

     詳細を見る

    出版者・発行元:Science Advances  

    Head-and-neck squamous cell carcinoma (HNSCC) is the sixth most common group of cancers in the world, and patients have a poor prognosis. Here, we present data indicating that YAP1 may be a strong driver of the onset and progression of oral SCC (OSCC), a major subtype of HNSCC. Mice with tongue-specific deletion of Mob1a/b and thus endogenous YAP1 hyperactivation underwent surprisingly rapid and highly reproducible tumorigenesis, developing tongue carcinoma in situ within 2 weeks and invasive SCC within 4 weeks. In humans, precancerous tongue dysplasia displays YAP1 activation correlating with reduced patient survival. Combinations of molecules mutated in OSCC may increase and sustain YAP1 activation to the point of oncogenicity. Strikingly, siRNA or pharmacological inhibition of YAP1 blocks murine OSCC onset in vitro and in vivo. Our work justifies targeting YAP1 as therapy for OSCC and perhaps HNSCC, and our mouse model represents a powerful tool for evaluating these agents.

    DOI: 10.1126/sciadv.adn0844

    Scopus

  • Trousseau's Syndrome with Advanced Neuroendocrine Carcinoma of Colon: A Case Report

    Ohmura, H; Tobo, T; Mimori, K; Baba, E; Horiuchi, T

    CASE REPORTS IN ONCOLOGY   16 ( 1 )   484 - 490   2023年12月   ISSN:1662-6575

     詳細を見る

    記述言語:英語   出版者・発行元:Case Reports in Oncology  

    Here, we present a 69-year-old female with advanced neuroendocrine carcinoma (NEC) of colon with multiple liver, bone, and kidney metastases who developed Trousseau's syndrome. The patient received etoposide plus cisplatin (EP) as the first-line therapy; however, after single administration of EP, she developed the severe lower-limb edema and EP was considered to be intolerable. Etoposide plus carboplatin was administered as the second-line therapy and after 3 cycles of administration, the progressive disease (PD) was confirmed and 5-fluorouracil + leucovorin + irinotecan (FOLFIRI) plus ramucirumab was administered as the third-line therapy. However, PD was confirmed after 3 cycles of the therapy, and she was to receive the best supportive care and was hospitalized in our hospital. Four weeks after hospitalization, mild impaired consciousness and dysarthria were observed. Blood tests showed coagulation abnormalities including elevation of plasma fibrin/fibrinogen degradation products (FDPs) and D-dimer levels, and the diffusion-weighted image of magnetic resonance imaging (MRI) of the head showed multiple cerebral infarcts. She was diagnosed with Trousseau's syndrome due to the progression of NEC and intravenous unfractionated heparin was administered as anticoagulant therapy. After the administration of heparin, plasma FDP and D-dimer levels decreased; however, due to the progression of NEC, the patient died 6 weeks after hospitalization. This is the first report of NEC of the colon that developed Trousseau's syndrome.

    DOI: 10.1159/000530927

    Web of Science

    Scopus

    PubMed

  • Real-time telementoring with 3D drawing annotation in robotic surgery

    Nakanoko, T; Oki, E; Ota, M; Ikenaga, N; Hisamatsu, Y; Toshima, T; Kanno, T; Tadano, K; Kawashima, K; Ohuchida, K; Morohashi, H; Ebihara, Y; Mimori, K; Nakamura, M; Yoshizumi, T; Hakamada, K; Hirano, S; Ikeda, N; Mori, M

    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES   37 ( 12 )   9676 - 9683   2023年12月   ISSN:0930-2794 eISSN:1432-2218

     詳細を見る

    記述言語:英語   出版者・発行元:Surgical Endoscopy  

    Background: In telementoring, differences in teaching methods affect local surgeons’ comprehension. Because the object to be operated on is a three-dimensional (3D) structure, voice or 2D annotation may not be sufficient to convey the instructor’s intention. In this study, we examined the usefulness of telementoring using 3D drawing annotations in robotic surgery. Methods: Kyushu University and Beppu Hospital are located 140 km apart, and the study was conducted using a Saroa™ surgical robot by RIVERFIELD Inc. using a commercial guarantee network on optical fiber. Twenty medical students performed vertical mattress suturing using a swine intestinal tract under surgical guidance at the Center for Advanced Medical Innovation Kyushu University. Surgical guidance was provided by Beppu Hospital using voice, 2D, and 3D drawing annotations. All robot operations were performed using 3D images, and only the annotations were independently switched between voice and 2D and 3D images. The operation time, needle movement, and performance were also evaluated. Results: The 3D annotation group tended to have a shorter working time than the control group (25.6 ± 63.2 vs. − 36.7 ± 65.4 min, P = 0.06). The 3D annotation group had fewer retries than the control group (1.3 ± 1.7 vs. − 1.1 ± 0.7, P = 0.006), and there was a tendency for fewer needle drops (0.4 ± 0.7 vs. − 0.5 ± 0.9, P = 0.06). The 3D annotation group scored significantly higher than the control group on the Global Evaluate Assessment of Robot Skills (16.8 ± 2.0 vs. 22.8 ± 2.4, P = 0.04). The 3D annotation group also scored higher than the voice (13.4 ± 1.2) and 2D annotation (16.2 ± 1.8) groups (3D vs. voice: P = 0.03, 3D vs. 2D: P = 0.03). Conclusion: Telementoring using 3D drawing annotation was shown to provide good comprehension and a smooth operation for local surgeons. Graphical abstract: [Figure not available: see fulltext.]

    DOI: 10.1007/s00464-023-10521-z

    Web of Science

    Scopus

    PubMed

  • Transducin Beta-Like 2 is a Potential Driver Gene that Adapts to Endoplasmic Reticulum Stress to Promote Tumor Growth of Lung Adenocarcinoma. 査読 国際誌

    Kosai K, Masuda T, Kitagawa A, Tobo T, Ono Y, Ando Y, Takahashi J, Haratake N, Kohno M, Takenaka T, Yoshizumi T, Mimori K.

    Ann Surg Oncol.   30 ( (12) )   7538 - 7548   2023年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-023-13864-y.

  • ASO Visual Abstract: Transducin Beta-like 2 is a Potential Driver Gene that Adapts to Endoplasmic Reticulum Stress to Promote Tumor Growth of Lung Adenocarcinoma

    Kosai, K; Masuda, T; Kitagawa, A; Tobo, T; Ono, Y; Ando, Y; Takahashi, J; Haratake, N; Kohno, M; Takenaka, T; Yoshizumi, T; Mimori, K

    ANNALS OF SURGICAL ONCOLOGY   30 ( 12 )   7597 - 7598   2023年11月   ISSN:1068-9265 eISSN:1534-4681

  • Transducin Beta-Like 2 is a Potential Driver Gene that Adapts to Endoplasmic Reticulum Stress to Promote Tumor Growth of Lung Adenocarcinoma

    Kosai, K; Masuda, T; Kitagawa, A; Tobo, T; Ono, Y; Ando, Y; Takahashi, J; Haratake, N; Kohno, M; Takenaka, T; Yoshizumi, T; Mimori, K

    ANNALS OF SURGICAL ONCOLOGY   30 ( 12 )   7538 - 7548   2023年11月   ISSN:1068-9265 eISSN:1534-4681

     詳細を見る

    記述言語:英語   出版者・発行元:Annals of Surgical Oncology  

    Background: Endoplasmic reticulum (ER) stress has a close relation with cancer progression. Blocking the adaptive pathway of ER stress could be an anticancer strategy. Here, we identified an ER stress-related gene, Transducin beta-like 2 (TBL2), an ER-localized type I transmembrane protein, on increased chromosome 7q as a candidate driver gene of lung adenocarcinoma (LUAD). Methods: The association between TBL2 mRNA expression and prognostic outcomes and clinicopathological factors was analyzed using The Cancer Genome Atlas (TCGA) datasets of LUAD and lung squamous cell carcinoma (LUSC). Localization of TBL2 in tumor tissues was observed by immunohistochemical staining. Gene set enrichment analysis (GSEA) was conducted using TCGA dataset. In vitro cell proliferation assays were performed using TBL2 knockdown LUAD cells, LUSC cells, and LUAD cells overexpressing TBL2. Apoptosis and ATF4 expression (ER stress marker) were evaluated by western blotting. Results: TBL2 was overexpressed in LUAD and LUSC cells. Multivariate analysis indicated high TBL2 mRNA expression was an independent poor prognostic factor of LUAD. GSEA revealed high TBL2 expression was positively correlated to the ER stress response in LUAD. TBL2 knockdown attenuated LUAD cell proliferation under ER stress. TBL2 inhibited apoptosis in LUAD cells under ER stress. TBL2 knockdown reduced ATF4 expression under ER stress. Conclusions: TBL2 may be a novel driver gene that facilitates cell proliferation, possibly by upregulating ATF4 expression followed by adaptation to ER stress, and it is a poor prognostic biomarker of LUAD.

    DOI: 10.1245/s10434-023-13864-y

    Web of Science

    Scopus

    PubMed

  • Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers

    Kobayashi, Y; Niida, A; Nagayama, S; Saeki, K; Haeno, H; Takahashi, KK; Hayashi, S; Ozato, Y; Saito, H; Hasegawa, T; Nakamura, H; Tobo, T; Kitagawa, A; Sato, K; Shimizu, D; Hirata, H; Hisamatsu, Y; Toshima, T; Yonemura, Y; Masuda, T; Mizuno, S; Kawazu, M; Kohsaka, S; Ueno, T; Mano, H; Ishihara, S; Uemura, M; Mori, M; Doki, Y; Eguchi, H; Oshima, M; Suzuki, Y; Shibata, T; Mimori, K

    BRITISH JOURNAL OF CANCER   129 ( 7 )   1105 - 1118   2023年10月   ISSN:0007-0920 eISSN:1532-1827

     詳細を見る

    記述言語:英語   出版者・発行元:British Journal of Cancer  

    Background: Intratumor heterogeneity (ITH) in microsatellite instability-high (MSI-H) colorectal cancer (CRC) has been poorly studied. We aimed to clarify how the ITH of MSI-H CRCs is generated in cancer evolution and how immune selective pressure affects ITH. Methods: We reanalyzed public whole-exome sequencing data on 246 MSI-H CRCs. In addition, we performed a multi-region analysis from 6 MSI-H CRCs. To verify the process of subclonal immune escape accumulation, a novel computational model of cancer evolution under immune pressure was developed. Results: Our analysis presented the enrichment of functional genomic alterations in antigen-presentation machinery (APM). Associative analysis of neoantigens indicated the generation of immune escape mechanisms via HLA alterations. Multiregion analysis revealed the clonal acquisition of driver mutations and subclonal accumulation of APM defects in MSI-H CRCs. Examination of variant allele frequencies demonstrated that subclonal mutations tend to be subjected to selective sweep. Computational simulations of tumour progression with the interaction of immune cells successfully verified the subclonal accumulation of immune escape mutations and suggested the efficacy of early initiation of an immune checkpoint inhibitor (ICI) -based treatment. Conclusions: Our results demonstrate the heterogeneous acquisition of immune escape mechanisms in MSI-H CRCs by Darwinian selection, providing novel insights into ICI-based treatment strategies.

    DOI: 10.1038/s41416-023-02395-8

    Web of Science

    Scopus

    PubMed

  • Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers. 査読 国際誌

    Kobayashi Y, Niida A, Nagayama S, Saeki K, Haeno H, Takahashi KK, Hayashi S, Ozato Y, Saito H, Hasegawa T, Nakamura H, Tobo T, Kitagawa A, Sato K, Shimizu D, Hirata H, Hisamatsu Y, Toshima T, Yonemura Y, Masuda T, Mizuno S, Kawazu M, Kohsaka S, Ueno T, Mano H, Ishihara S, Uemura M, Mori M, Doki Y, Eguchi H, Oshima M, Suzuki Y, Shibata T, Mimori K.

    Br J Cancer.   129 ( (7) )   1105 - 1118   2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41416-023-02395-8.

  • Successful multidisciplinary treatment with complete response to atezolizumab plus bevacizumab in a 90-year-old patient with hepatocellular carcinoma recurrence

    Hosoda, K; Toshima, T; Takahashi, J; Yonemura, Y; Hisamatsu, Y; Hirose, K; Masuda, T; Motomura, Y; Abe, T; Ando, Y; Dairaku, K; Nakano, Y; Hashimoto, M; Hiraki, Y; Soejima, Y; Yoshizumi, T; Mimori, K

    INTERNATIONAL CANCER CONFERENCE JOURNAL   12 ( 4 )   274 - 278   2023年10月   ISSN:2192-3183

     詳細を見る

  • 集学的治療を行い、アテゾリズマブ+ベバシズマブ併用療法によって完全奏効を達成した90歳の肝細胞癌再発患者の症例(Successful multidisciplinary treatment with complete response to atezolizumab plus bevacizumab in a 90-year-old patient with hepatocellular carcinoma recurrence)

    Hosoda Kiyotaka, Toshima Takeo, Takahashi Junichi, Yonemura Yusuke, Hisamatsu Yuichi, Hirose Kosuke, Masuda Takaaki, Motomura Yushi, Abe Tadashi, Ando Yuki, Dairaku Katsushi, Nakano Yusuke, Hashimoto Masahiro, Hiraki Yoshiki, Soejima Yuji, Yoshizumi Tomoharu, Mimori Koshi

    International Cancer Conference Journal   12 ( 4 )   274 - 278   2023年10月

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

    症例は90歳女性。非B非C型肝炎であり、18ヵ月前に原発性肝細胞癌に対して腹腔鏡下肝切除術が施行された。術後6ヵ月、肝細胞癌再発に対して経カテーテル的肝動脈化学塞栓療法(TACE)が施行されたが、その1年後に2回目の再発が認められた。レンバチニブ(LEN)8mg/日投与を開始したところ、1週間後に極度の疲労や食欲不振などの重篤な有害事象(AE)が出現し、投与量を4mg/日に減量したがAEの管理は困難であった。そこで、LEN導入から1ヵ月後に化学療法をアテゾリズマブ+ベバシズマブ併用療法に変更した。その結果、副作用はほとんど認められず、腫瘍の退縮が認められた。本レジメンを8ヵ月間、10サイクル続け、最終的に完全奏効(CR)を達成した。CR達成後1年経過しても再発はみられていない。

  • Fibrolamellar hepatocellular carcinoma: a case report and gene analysis

    Watanabe, A; Harimoto, N; Saito, H; Kawabata-Iwakawa, R; Seki, T; Muranushi, R; Hoshino, K; Hagiwara, K; Ishii, N; Tsukagoshi, M; Igarashi, T; Araki, K; Ikota, H; Ishige, T; Mimori, K; Shirabe, K

    SURGICAL CASE REPORTS   9 ( 1 )   168   2023年9月   ISSN:2198-7793

     詳細を見る

  • Fibrolamellar hepatocellular carcinoma: a case report and gene analysis. 査読 国際誌

    Watanabe A, Harimoto N, Saito H, Kawabata-Iwakawa R, Seki T, Muranushi R, Hoshino K, Hagiwara K, Ishii N, Tsukagoshi M, Igarashi T, Araki K, Ikota H, Ishige T, Mimori K, Shirabe K.

    Surg Case Rep.   9 ( (1) )   168. - 168.   2023年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s40792-023-01751-3.

  • Fibrolamellar hepatocellular carcinoma 1症例報告と遺伝子解析(Fibrolamellar hepatocellular carcinoma: a case report and gene analysis)

    Watanabe Akira, Harimoto Norifumi, Saito Hideyuki, Kawabata-Iwakawa Reika, Seki Takaomi, Muranushi Ryo, Hoshino Kouki, Hagiwara Kei, Ishii Norihiro, Tsukagoshi Mariko, Igarashi Takamichi, Araki Kenichiro, Ikota Hayato, Ishige Takashi, Mimori Koshi, Shirabe Ken

    Surgical Case Reports   9   1 of 8 - 8 of 8   2023年9月

     詳細を見る

    記述言語:英語   出版者・発行元:Springer Berlin Heidelberg  

    症例は14歳男児で、虫垂炎の評価のため行った腹部CTで28mm大の肝腫瘍が検出され、次第に増大した。当科紹介時の腹部CTでは35mm大の固形腫瘍と、右門脈の閉塞および腫瘍内の石灰化が認められた。悪性のfibrolamellar hepatocellular carcinoma(FL-HCC)と診断し、右肝切除を行った。術後経過は良好で、術後9日目に退院した。病理組織学的所見では、腫瘍のcentral scarは過形成と線維化を示し、ヒアリン石灰化を伴っていた。腫瘍細胞には肥大した核と明瞭な核小体、好酸性顆粒状細胞質が認められ、切除リンパ節に腫瘍細胞の転移がみられ、FL-HCCと診断した。初回手術から12ヵ月後に肝十二指腸間膜靱帯で単発のリンパ節再発を認め、再発腫瘍に対してリンパ節切除を行った。切除標本(原発巣、リンパ節転移巣、正常肝)を用いてRNAシークエンシング(RNA-seq)と標的遺伝子の変異解析を行った。RNA-seqでは、原発巣と転移巣の両方でDNAJB1-PRKACAが検出された。本症例の遺伝子発現は過去のFL-HCC症例と類似していたが、若年患者のHCC症例とは異なるクラスターであった。

  • The comprehensive review of gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) from diagnosis and treatment

    Iwatsuki, M; Matsumoto, C; Mimori, K; Baba, H

    ANNALS OF GASTROENTEROLOGICAL SURGERY   7 ( 5 )   725 - 732   2023年9月   ISSN:2475-0328

     詳細を見る

    記述言語:英語   出版者・発行元:Annals of Gastroenterological Surgery  

    Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) was first proposed by Wothley et al. in 2012 as a rare familial gastric cancer syndrome associated with an autosomal dominant form of inheritance. GAPPS is characterized by gastric basal gland polyposis from the hilum to the body of the stomach. Li et al. in 2016 showed that the cause of the disease is a point mutation in the promotor 1B region of the APC gene, and genetic testing was used to confirm the diagnosis. If the patient has already developed gastric cancer, treatment should be based on the usual treatment for gastric cancer. If no distant metastases exist, a good prognosis can be expected by performing a total gastrectomy. On the other hand, patients with distant metastasis have a poor prognosis. In the case of dysplasia, prophylactic total gastrectomy is recommended, but because it is highly invasive and postoperative postgastrectomy syndrome must be considered, the decision should be made with careful consideration of the patient's background. Therefore, there are no guidelines for screening for GAPPS, the timing of prophylactic total gastrectomy, or methods of endoscopic surveillance. Because GAPPS is a rare disease, its natural history is still unclear. Further case series are needed to elucidate the molecular biology and clinicopathological features of GAPPS and to establish clinical management, including diagnosis, treatment, and surveillance. In this review, we provide an overview of GAPPS, its clinical management, and its problems, which will be useful for the treatment of GAPPS.

    DOI: 10.1002/ags3.12708

    Web of Science

    Scopus

    PubMed

  • Hot spring bathing practices have a positive effect on mental health in Japan

    Takeda, M; Nakamura, H; Otsu, H; Mimori, K; Maeda, T; Managi, S

    HELIYON   9 ( 9 )   e19631   2023年9月   ISSN:24058440 eISSN:2405-8440

     詳細を見る

    記述言語:英語   出版者・発行元:Heliyon  

    Hot springs have long been used for medical purposes throughout the world. Recently, the positive effects of hot spa-bathing on circulatory diseases have been reported, while there are few reports on the mental effects of hot spa-bathing. Therefore, the purpose of this study was to clarify the relationship between hot spa-bathing habits and mental health throughout Japan. We conducted a nationwide online survey, including questions on bathing behavior, subjective satisfaction, lifestyle, and illness. The results showed a significant positive correlation between hot spa-bathing habits and multiple subjective satisfaction levels regarding mental health effects. The factor analysis results indicated that hot spa-bathing habits tended to be associated with good mental health, high health consciousness, and disease. Our study revealed that subjective satisfaction was higher among individuals with hot spa-bathing habits, suggesting that the hot spring spa-bathing habit may have a positive influence on mental health.

    DOI: 10.1016/j.heliyon.2023.e19631

    Web of Science

    Scopus

    PubMed

  • Telesurgery and telesurgical support using a double-surgeon cockpit system allowing manipulation from two locations. 査読 国際誌

    Oki E, Ota M, Nakanoko T, Tanaka Y, Toyota S, Hu Q, Nakaji Y, Nakanishi R, Ando K, Kimura Y, Hisamatsu Y, Mimori K, Takahashi Y, Morohashi H, Kanno T, Tadano K, Kawashima K, Takano H, Ebihara Y, Shiota M, Inokuchi J, Eto M, Yoshizumi T, Hakamada K, Hirano S, Mori M.

    Surg Endosc.   37 ( (8) )   6071 - 6078   2023年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00464-023-10061-6.

  • Hot spring bathing practices have a positive effect on mental health in Japan. 査読 国際誌

    Takeda M, Nakamura H, Otsu H, Mimori K, Maeda T, Managi S.

    Heliyon.   9 ( (9) )   2023年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.heliyon.2023.e19631.

  • Successful multidisciplinary treatment with complete response to atezolizumab plus bevacizumab in a 90-year-old patient with hepatocellular carcinoma recurrence. 査読 国際誌

    Hosoda K, Toshima T, Takahashi J, Yonemura Y, Hisamatsu Y, Hirose K, Masuda T, Motomura Y, Abe T, Ando Y, Dairaku K, Nakano Y, Hashimoto M, Hiraki Y, Soejima Y, Yoshizumi T, Mimori K.

    Int Cancer Conf J.   12 ( (4) )   274 - 278   2023年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s13691-023-00618-6.

  • Trousseau's Syndrome with Advanced Neuroendocrine Carcinoma of Colon: A Case Report. 査読 国際誌

    Ohmura H, Tobo T, Mimori K, Baba E, Horiuchi T.

    Case Rep Oncol.   16 ( (1) )   484 - 490   2023年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1159/000530927.

  • The comprehensive review of gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) from diagnosis and treatment. 査読 国際誌

    Iwatsuki M, Matsumoto C, Mimori K, Baba H.

    Ann Gastroenterol Surg.   7 ( (5) )   725 - 732   2023年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/ags3.12708.

  • Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma

    Kitagawa, A; Osawa, T; Noda, M; Kobayashi, Y; Aki, S; Nakano, Y; Saito, T; Shimizu, D; Komatsu, H; Sugaya, M; Takahashi, J; Kosai, K; Takao, S; Motomura, Y; Sato, K; Hu, QJ; Fujii, A; Wakiyama, H; Tobo, T; Uchida, H; Sugimachi, K; Shibata, K; Utsunomiya, T; Kobayashi, S; Ishii, H; Hasegawa, T; Masuda, T; Matsui, Y; Niida, A; Soga, T; Suzuki, Y; Miyano, S; Aburatani, H; Doki, Y; Eguchi, H; Mori, M; Nakayama, KI; Shimamura, T; Shibata, T; Mimori, K

    BRITISH JOURNAL OF CANCER   128 ( 12 )   2206 - 2217   2023年6月   ISSN:0007-0920 eISSN:1532-1827

     詳細を見る

    記述言語:英語   出版者・発行元:British Journal of Cancer  

    Background: Driver alterations may represent novel candidates for driver gene-guided therapy; however, intrahepatic cholangiocarcinoma (ICC) with multiple genomic aberrations makes them intractable. Therefore, the pathogenesis and metabolic changes of ICC need to be understood to develop new treatment strategies. We aimed to unravel the evolution of ICC and identify ICC-specific metabolic characteristics to investigate the metabolic pathway associated with ICC development using multiregional sampling to encompass the intra- and inter-tumoral heterogeneity. Methods: We performed the genomic, transcriptomic, proteomic and metabolomic analysis of 39–77 ICC tumour samples and eleven normal samples. Further, we analysed their cell proliferation and viability. Results: We demonstrated that intra-tumoral heterogeneity of ICCs with distinct driver genes per case exhibited neutral evolution, regardless of their tumour stage. Upregulation of BCAT1 and BCAT2 indicated the involvement of ‘Val Leu Ile degradation pathway’. ICCs exhibit the accumulation of ubiquitous metabolites, such as branched-chain amino acids including valine, leucine, and isoleucine, to negatively affect cancer prognosis. We revealed that this metabolic pathway was almost ubiquitously altered in all cases with genomic diversity and might play important roles in tumour progression and overall survival. Conclusions: We propose a novel ICC onco-metabolic pathway that could enable the development of new therapeutic interventions. [Figure not available: see fulltext.]

    DOI: 10.1038/s41416-023-02256-4

    Web of Science

    Scopus

    PubMed

  • Telesurgery and telesurgical support using a double-surgeon cockpit system allowing manipulation from two locations

    Oki, E; Ota, M; Nakanoko, T; Tanaka, Y; Toyota, S; Hu, QJ; Nakaji, Y; Nakanishi, R; Ando, K; Kimura, Y; Hisamatsu, Y; Mimori, K; Takahashi, Y; Morohashi, H; Kanno, T; Tadano, K; Kawashima, K; Takano, H; Ebihara, Y; Shiota, M; Inokuchi, J; Eto, M; Yoshizumi, T; Hakamada, K; Hirano, S; Mori, M

    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES   37 ( 8 )   6071 - 6078   2023年5月   ISSN:0930-2794 eISSN:1432-2218

     詳細を見る

    記述言語:英語   出版者・発行元:Surgical Endoscopy  

    Background: Although several studies on telesurgery have been reported globally, a clinically applicable technique has not yet been developed. As part of a telesurgical study series conducted by the Japan Surgical Society, this study describes the first application of a double-surgeon cockpit system to telesurgery. Methods: Surgeon cockpits were installed at a local site and a remote site 140 km away. Three healthy pigs weighing between 26 and 29 kg were selected for surgery. Non-specialized surgeons performed emergency hemostasis, cholecystectomy, and renal vein ligation with remote assistance using the double-surgeon cockpits and specialized surgeons performed actual telesurgery. Additionally, the impact of adding internet protocol security (IPsec) encryption to the internet protocol-virtual private network (IP-VPN) line on communication was evaluated to address clinical security concerns. Results: The average time required for remote emergency hemostasis with the double-surgeon cockpit system was 10.64 s. A non-specialized surgeon could safely perform cholecystectomy or renal vein ligation with remote assistance. Global Evaluative Assessment of Robotic Skills and System Usability Scale scores were higher for telesurgical support-assisted surgery by a non-specialized surgeon using the double-surgeon cockpits than for telesurgery performed by a specialized surgeon without the double-cockpit system. Adding IPsec encryption to the IP-VPN did not have a significant impact on communication. Conclusion: Telesurgical support through our double-surgeon cockpit system is feasible as first step toward clinical telesurgery.

    DOI: 10.1007/s00464-023-10061-6

    Web of Science

    Scopus

    PubMed

  • Disclosing quantitative RT-PCR raw data during manuscript submission: a call for action

    Untergasser A., Hellemans J., Pfaffl M.W., Ruijter J.M., van den Hoff M.J.B., Dragomir M.P., Adamoski D., Dias S.M.G., Reis R.M., Ferracin M., Dias-Neto E., Marsh I., Kubista M., Fabbri M., Goel A., Slabý O., Knutsen E., Chen B., Negrini M., Mimori K., Pichler M., Papatriantafyllou M., Anfossi S., Schmittgen T.D., Huggett J., Bustin S., Vandesompele J., Calin G.A.

    Molecular Oncology   17 ( 5 )   713 - 717   2023年5月   ISSN:15747891

     詳細を見る

    記述言語:英語   出版者・発行元:Molecular Oncology  

    Accuracy and transparency of scientific data are becoming more and more relevant with the increasing concern regarding the evaluation of data reproducibility in many research areas. This concern is also true for quantifying coding and noncoding RNAs, with the remarkable increase in publications reporting RNA profiling and sequencing studies. To address the problem, we propose the following recommendations: (a) accurate documentation of experimental procedures in Materials and methods (and not only in the supplementary information, as many journals have a strict mandate for making Materials and methods as visible as possible in the main text); (b) submission of RT-qPCR raw data for all experiments reported; and (c) adoption of a unified, simple format for submitted RT-qPCR raw data. The Real-time PCR Data Essential Spreadsheet Format (RDES) was created for this purpose.

    DOI: 10.1002/1878-0261.13418

    Scopus

    PubMed

  • Disclosing quantitative RT-PCR raw data during manuscript submission: a call for action. 査読 国際誌

    Mol Oncol.   2023年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/1878-0261.13418.

  • Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma. 招待 査読 国際誌

    Kitagawa A, Osawa T, Noda M, Kobayashi Y, Aki S, Nakano Y, Saito T, Shimizu D, Komatsu H, Sugaya M, Takahashi J, Kosai K, Takao S, Motomura Y, Sato K, Hu Q, Fujii A, Wakiyama H, Tobo T, Uchida H, Sugimachi K, Shibata K, Utsunomiya T, Kobayashi S, Ishii H, Hasegawa T, Masuda T, Matsui Y, Niida A, Soga T, Suzuki Y, Miyano S, Aburatani H, Doki Y, Eguchi H, Mori M, Nakayama KI, Shimamura T, Shibata T, Mimori K.

    British Journal of Cancer   128 ( 12 )   2206 - 2217   2023年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Dynamic Changes in Peripheral Systemic Immunity Markers During Chemotherapy in HER2-negative Advanced Breast Cancer. 査読 国際誌

    Masuda T, Ueo H, Okumura Y, Kai Y, Ando Y, Masuguchi K, Kitagawa M, Kitagawa A, Hayashi N, Tsuruda Y, Hisamatsu Y, Suehiro S, Ohmura H, Fujiyoshi K, Tanaka F, Mimori K.

    Cancer Genomics Proteomics.   20 ( 2 )   182 - 194   2023年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/cgp.20373.

  • Novel and classic approaches for managing gastrointestinal cancers. 査読 国際誌

    Mimori K.

    Ann Gastroenterol Surg.   7 ( 2 )   196 - 197   2023年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/ags3.12670.

  • Sustained Epigenetic Carcinogenic Alteration in Hepatocellular Carcinoma Arising on the Liver After Viral Eradication

    Sugimachi, K; Shimagaki, T; Mano, Y; Onishi, E; Morita, M; Toh, Y; Mimori, K

    ANNALS OF SURGICAL ONCOLOGY   30 ( SUPPL 1 )   S97 - S97   2023年3月   ISSN:1068-9265 eISSN:1534-4681

     詳細を見る

  • Novel and classic approaches for managing gastrointestinal cancers

    Mimori, K

    ANNALS OF GASTROENTEROLOGICAL SURGERY   7 ( 2 )   196 - 197   2023年3月   ISSN:2475-0328

     詳細を見る

    記述言語:英語   出版者・発行元:Annals of Gastroenterological Surgery  

    DOI: 10.1002/ags3.12670

    Web of Science

    Scopus

    PubMed

  • Dynamic Changes in Peripheral Systemic Immunity Markers During Chemotherapy in HER2-negative Advanced Breast Cancer

    Masuda, T; Ueo, H; Okumura, Y; Kai, YCR; Ando, Y; Masuguchi, K; Kitagawa, M; Kitagawa, A; Hayashi, N; Tsuruda, Y; Hisamatsu, Y; Suehiro, S; Ohmura, H; Fujiyoshi, K; Tanaka, F; Mimori, K

    CANCER GENOMICS & PROTEOMICS   20 ( 2 )   182 - 194   2023年3月   ISSN:1109-6535 eISSN:1790-6245

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Genomics and Proteomics  

    Background/Aim: The immune system has a pivotal role in modulating the response to chemotherapy in breast cancer (BC). However, the immune status during chemotherapy remains unclear. We evaluated the sequential changes in peripheral systemic immunity markers in BC patients treated with various chemotherapeutic agents. Materials and Methods: We examined the correlation between the peripheral systemic immunity markers, neutrophil-to-lymphocyte ratio (NLR), absolute lymphocyte count (ALC) and the local cytolytic activity (CYT) score obtained by quantitative reverse-transcription polymerase chain reaction of 84 preoperative BC patients. Next, we observed the sequential changes in the peripheral systemic immunity markers during treatment with four anticancer drugs: oral 5-fluorouracil derivative; S-1, epirubicin plus cyclophosphamide; paclitaxel plus the anti-vascular endothelial growth factor antibody bevacizumab, and eribulin in 172 HER2-negative advanced BC patients. Finally, we examined the correlation between the changes in the peripheral systemic immunity markers, time to treatment failure (TTF) and progression-free survival (PFS). Results: A negative correlation was found between ALC and NLR. ALC-low and NLR-high cases were positively associated with CYT score-low cases. The ratio of ALC-increase and NLR-decrease varies depending on the anticancer drugs used. The responder group (TTF .3 months) had a higher NLR-decrease ratio than the nonresponder group (TTF <3 months). Patients with a high NLR-decrease ratio showed higher PFS. Conclusion: The change in ALC or NLR varies according to the anticancer drugs, suggesting differential immunomodulatory effects of the drugs. Furthermore, the change in NLR reflects the therapeutic efficacy of chemotherapy in advanced BC.

    DOI: 10.21873/cgp.20373

    Web of Science

    Scopus

    PubMed

  • Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer

    Hu, QJ; Masuda, T; Oki, E; Mimori, K; Yoshizumi, T

    CANCER SCIENCE   114   1177 - 1177   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Tumor necrosis factor superfamily member 4 is a candidate driver gene for hepatocellular carcinoma

    Hosoda, K; Masuda, T; Saito, H; Ando, Y; Abe, T; Dairaku, K; Nakano, Y; Hashimoto, M; Hiraki, Y; Yonemura, Y; Toshima, T; Hisamatsu, Y; Takahashi, J; Soejima, Y; Mimori, K

    CANCER SCIENCE   114   2051 - 2051   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Translational research to identify genetic alterations involved in resistance to treatments such as radiotherapy

    Hirata, H; Akimoto, T; Mimori, K

    CANCER SCIENCE   114   885 - 885   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Transducin beta-like 2 (TBL2) on chromosome 7 is a candidate driver gene of lung adenocarcinoma (LUAD)

    Ono, Y; Masuda, T; Kosai, K; Shibuta, S; Miyata, Y; Ando, Y; Motomura, Y; Abe, T; Takahashi, J; Hisamatsu, Y; Toshima, T; Yonemura, Y; Takenaka, T; Yoshizumi, T; Mimori, K

    CANCER SCIENCE   114   1843 - 1843   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • The effect of preoperative chemotherapies for microenvironment in esophageal squamous cell carcinoma

    Hirose, K; Masuda, T; Ando, Y; Toshima, T; Mimori, K

    CANCER SCIENCE   114   504 - 504   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Identification of SHARPIN, a novel candidate driver gene of colorectal cancer, and its clinical significance

    Nakano, Y; Masuda, T; Hisamatsu, Y; Toshima, T; Yonemura, Y; Uemura, M; Eguchi, H; Doki, Y; Mimori, K

    CANCER SCIENCE   114   785 - 785   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Identification of candidate driver gene C3orf1 by chromosome copy number analysis in ESCC

    Hiraki, Y; Masuda, T; Motomura, Y; Dairaku, K; Mochizuki, K; Abe, T; Ando, Y; Takahashi, J; Nakano, Y; Hashimoto, M; Hosoda, K; Hisamatsu, Y; Toshima, T; Yonemura, Y; Mimori, K

    CANCER SCIENCE   114   2050 - 2050   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • High-speed ion conductance microscope to reveal the nanoscale physical properties of metastatic intestinal cancer cells

    Sun, LH; Wang, D; Okuda, S; Nguye, HG; Yamamoto, D; Nakayama, M; Oshima, H; Saito, H; Kouyama, Y; Mimori, K; Ando, T; Watanabe, S; Oshima, M

    CANCER SCIENCE   114   467 - 467   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • High-speed ion conductance microscope to reveal the nanoscale physical properties of metastatic intestinal cancer cells

    Sun, LH; Wang, D; Okuda, S; Nguye, HG; Yamamoto, D; Nakayama, M; Oshima, H; Saito, H; Kouyama, Y; Mimori, K; Ando, T; Watanabe, S; Oshima, M

    CANCER SCIENCE   114   779 - 779   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Genomic characterizations of Japanese breast cancer

    Ando, Y; Masuda, T; Hosoda, K; Hashimoto, M; Nakano, Y; Dairaku, K; Mochizuki, K; Abe, T; Hiraki, Y; Motomura, Y; Takahashi, J; Hisamatsu, Y; Toshima, T; Yonemura, Y; Mimori, K

    CANCER SCIENCE   114   2162 - 2162   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Genetic intratumor heterogeneity and clonal evolution in cancers treated with radiotherapy

    Hirata, H; Akimoto, T; Mimori, K

    CANCER SCIENCE   114   172 - 172   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Exosome promotes peritoneal metastasis in gastric cancer

    Shibuta, S; Masuda, T; Nanbara, S; Takahashi, J; Hisamatsu, Y; Toshima, T; Yonemura, Y; Yoshizumi, T; Mimori, K

    CANCER SCIENCE   114   1368 - 1368   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Dynamic changes in peripheral systemic immunity markers during various chemotherapies in advanced breast cancer

    Masuda, T; Ando, Y; Motomura, Y; Abe, T; Hashimoto, M; Nakano, Y; Dairaku, K; Hiraki, Y; Hosoda, K; Takahashi, J; Hisamatsu, Y; Toshima, T; Yonemura, Y; Mimori, K

    CANCER SCIENCE   114   2151 - 2151   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G plus cancer cells and SPP1+macrophages in colorectal cancer

    Ozato, Y; Kojima, Y; Kobayashi, Y; Hisamatsu, Y; Toshima, T; Yonemura, Y; Masuda, T; Kagawa, K; Goto, Y; Utou, M; Fukunaga, M; Gamachi, A; Imamura, K; Kuze, Y; Zenkoh, J; Suzuki, A; Niida, A; Hirose, H; Hayashi, S; Koseki, J; Oki, E; Fukuchi, S; Murakami, K; Tobo, T; Nagayama, S; Uemura, M; Sakamoto, T; Oshima, M; Doki, Y; Eguchi, H; Mori, M; Iwasaki, T; Oda, Y; Shibata, T; Suzuki, Y; Shimamura, T; Mimori, K

    CELL REPORTS   42 ( 1 )   111929   2023年1月   ISSN:2211-1247

     詳細を見る

    記述言語:英語   出版者・発行元:Cell Reports  

    The cellular interactions in the tumor microenvironment of colorectal cancer (CRC) are poorly understood, hindering patient treatment. In the current study, we investigate whether events occurring at the invasion front are of particular importance for CRC treatment strategies. To this end, we analyze CRC tissues by combining spatial transcriptomics from patients with a public single-cell transcriptomic atlas to determine cell-cell interactions at the invasion front. We show that CRC cells are localized specifically at the invasion front. These cells induce human leukocyte antigen G (HLA-G) to produce secreted phosphoprotein 1 (SPP1)+ macrophages while conferring CRC cells with anti-tumor immunity, as well as proliferative and invasive properties. Taken together, these findings highlight the signaling between CRC cell populations and stromal cell populations at the cellular level.

    DOI: 10.1016/j.celrep.2022.111929

    Web of Science

    Scopus

    PubMed

  • Mutated genes on ctDNA detecting postoperative recurrence presented reduced neoantigens in primary tumors in colorectal cancer cases

    Nagayama, S; Kobayashi, Y; Fukunaga, M; Sakimura, S; Sugimachi, K; Sasaki, S; Masuda, T; Mafune, KI; Oshima, M; Shibata, T; Suzuki, Y; Mimori, K

    SCIENTIFIC REPORTS   13 ( 1 )   1366   2023年1月   ISSN:2045-2322

     詳細を見る

    記述言語:英語   出版者・発行元:Scientific Reports  

    The detection and sequencing of the mutated ctDNA is one of the irreplaceable clinical measures in the postoperative management of colorectal cancer (CRC) cases. However, we are curious to comprehend the essential traits of mutated genes comprising metastatic sites out of whole mutated genes in primary sites. In the current retrospective study, we conducted target resequencing of ctDNA using 47 plasma samples and established a cancer panel carrying the commonly mutated genes between primary and recurrent tumors. We found that mutated genes in ctDNA indicated immune-resistance traits with respect to the impaired ability to present neoantigens by loss of expression or binding affinity to HLA in the primary tumor. Compared with the estimated neoantigens from all mutated genes in primary tumors, the neoantigen peptides from commonly mutated genes on the panel showed abundant expression but no binding affinity to HLA. Therefore, ctDNA mutations can be frequently and postoperatively detected to identify recurrence; however, these mutated genes were derived from immune-tolerated clones owing to the loss of neoantigen presentation in primary CRC tumors.

    DOI: 10.1038/s41598-023-28575-3

    Web of Science

    Scopus

    PubMed

  • Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer. 査読 国際誌

    Ozato Y, Kojima Y, Kobayashi Y, Hisamatsu Y, Toshima T, Yonemura Y, Masuda T, Kagawa K, Goto Y, Utou M, Fukunaga M, Gamachi A, Imamura K, Kuze Y, Zenkoh J, Suzuki A, Niida A, Hirose H, Hayashi S, Koseki J, Oki E, Fukuchi S, Murakami K, Tobo T, Nagayama S, Uemura M, Sakamoto T, Oshima M, Doki Y, Eguchi H, Mori M, Iwasaki T, Oda Y, Shibata T, Suzuki Y, Shimamura T, Mimori K.

    Cell Rep.   42 ( 1 )   111929   2023年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.celrep.2022.111929.

  • Rab27b, a Regulator of Exosome Secretion, Is Associated With Peritoneal Metastases in Gastric Cancer. 査読 国際誌

    Nambara S, Masuda T, Hirose K, Hu Q, Tobo T, Ozato Y, Kurashige J, Hiraki Y, Hisamatsu Y, Iguchi T, Sugimachi K, Oki E, Yoshizumi T, Mimori K.

    Cancer Genomics Proteomics.   20 ( 1 )   30 - 39   2023年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/cgp.20362.

  • Prediction of tissue-of-origin of early stage cancers using serum miRNomes. 査読 国際誌

    6. Matsuzaki J, Kato K, Oono K, Tsuchiya N, Sudo K, Shimomura A, Tamura K, Shiino S, Kinoshita T, Daiko H, Wada T, Katai H, Ochiai H, Kanemitsu Y, Takamaru H, Abe S, Saito Y, Boku N, Kondo S, Ueno H, Okusaka T, Shimada K, Ohe Y, Asakura K, Yoshida Y, Watanabe SI, Asano N, Kawai A, Ohno M, Narita Y, Ishikawa M, Kato T, Fujimoto H, Niida S, Sakamoto H, Takizawa S, Akiba T, Okanohara D, Shiraishi K, Kohno T, Takeshita F, Nakagama H, Ota N, Ochiya T; Project Team for Development and Diagnostic Technology for Detection of miRNA in Body Fluids.

    JNCI Cancer Spectr.   7 ( 1 )   pkac080   2023年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/jncics/pkac080.

  • Mutated genes on ctDNA detecting postoperative recurrence presented reduced neoantigens in primary tumors in colorectal cancer cases. 査読 国際誌

    Nagayama S, Kobayashi Y, Fukunaga M, Sakimura S, Sugimachi K, Sasaki S, Masuda T, Mafune KI, Oshima M, Shibata T, Suzuki Y, Mimori K.

    Sci Rep   13 ( 1 )   1366   2023年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41598-023-28575-3.

  • 気胸を発症した悪性葉状腫瘍でパゾパニブに反応した1例(A case of malignant phyllodes tumor that responded to pazopanib and developed pneumothorax)

    Ohmura Hirofumi, Masuda Takaaki, Mimori Koshi, Baba Eishi, Horiuchi Takahiko

    International Cancer Conference Journal   12 ( 1 )   31 - 35   2023年1月

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

    症例は59歳女性で、他院にてトリプルネガティブ乳癌(cT3NXM0、cStage IIIB、浸潤性乳管癌)と診断され、左乳房切除術と腋窩リンパ節郭清を受けた。手術検体の病理組織学的検査では悪性葉状腫瘍に一致していた。術後4ヵ月、左胸A・B領域の悪性葉状腫瘍再発、最大径5cmの多発性肺転移、リンパ節転移と診断され、当院で全身化学療法を受けることになった。二次化学療法としてパゾパニブを投与した。治療開始2.5ヵ月後、CT検査で肺病変のサイズと空洞が減少したが、新たに左気胸を認めた。立位胸部X線では気胸の鑑別が困難であった。気胸の典型的な症状や身体所見である呼吸困難、胸痛、呼吸音減弱は認めなかった。気胸は小さく無症状であったため、パゾパニブ投与を中止し、胸部X線とCTで経過観察を行った。1週間後、CTで気胸の改善を確認した。化学療法をエリブリンに変更したが、エリブリン初回投与後に肺病変の急速な増大を認めたため、パゾパニブを再投与した。胸部X線とCTによる慎重な経過観察を行った結果、気胸の再発は認めなかった。

  • Rab27b, a Regulator of Exosome Secretion, Is Associated With Peritoneal Metastases in Gastric Cancer

    Nambara, S; Masuda, T; Hirose, K; Hu, QJ; Tobo, T; Ozato, Y; Kurashige, J; Hiraki, Y; Hisamatsu, Y; Iguchi, T; Sugimachi, K; Oki, E; Yoshizumi, T; Mimori, K

    CANCER GENOMICS & PROTEOMICS   20 ( 1 )   30 - 39   2023年1月   ISSN:1109-6535 eISSN:1790-6245

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Genomics and Proteomics  

    Background/Aim: Peritoneal metastasis (PM) of gastric cancer (GC) leads to poor clinical outcomes. Tumor-derived exosomes promote metastasis via communication between tumor cells and host cells. In this study, we investigated the effect of Rab27, which is required for exosome secretion, on the PM of GC. Materials and Methods: We established a stable knockdown of two Rab27 homologs, Rab27a and Rab27b, in human GC cells (58As9) with a high potential of PM. We examined the level of exosome secretion from Rab27-knockdown 58As9 cells by Western blotting and the ability of Rab27b knockdown to suppress PM in 58As9 cells using a mouse xenograft model. In vitro proliferation and invasion assays were performed in the Rab27b-knockdown cells. Next, Rab27b expression was evaluated in human GC tissues by immunohistochemistry. Finally, we assessed the clinicopathological and prognostic significance of Rab27b expression by RT-qPCR in both our and other TCGA datasets of GC. Results: Rab27a and Rab27b knockdown in 58As9 cells decreased the secretion of exosomes, characterized by the endocytic marker CD63.

    DOI: 10.21873/cgp.20362

    Web of Science

    Scopus

    PubMed

  • Identification of the Minimum Combination of Serum microRNAs to Predict the Recurrence of Colorectal Cancer Cases

    Yoshikawa, Y; Fukunaga, M; Takahashi, J; Shimizu, D; Masuda, T; Mizushima, T; Yamada, K; Mori, M; Eguchi, H; Doki, Y; Ochiya, T; Mimori, K

    ANNALS OF SURGICAL ONCOLOGY   30 ( 1 )   233 - 243   2023年1月   ISSN:1068-9265 eISSN:1534-4681

     詳細を見る

    記述言語:英語   出版者・発行元:Annals of Surgical Oncology  

    Background: Serum microRNAs (miRNAs) have been recognized as potential stable biomarkers for various types of cancer. Considering the clinical applications, there are certain critical requirements, such as minimizing the number of miRNAs, reproducibility in a longitudinal clinical course, and superiority to conventional tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9. This study aimed to identify serum miRNAs that indicate the recurrence of colorectal cancer (CRC), surpassing inter-tumor heterogeneity. Methods: We conducted an analysis of 434 serum samples from 91 patients with CRC and 71 healthy subjects. miRNAs were obtained from Toray Co., Ltd, and miRNA profiles were analyzed using a three-step approach. miRNAs that were highly expressed in patients with CRC than in the healthy controls in the screening phase, and those that were highly expressed in the preoperative samples than in the 1-month postoperative samples in the discovery phase, were extracted. In the validation phase, the extracted miRNAs were evaluated in 323 perioperative samples, in chronological order. Results: A total of 12 miRNAs (miR-25-3p, miR-451a, miR-1246, miR-1268b, miR-2392, miR-4480, miR-4648, miR-4732-5p, miR-4736, miR-6131, miR-6776-5p, and miR-6851-5p) were significantly concordant with the clinical findings of tumor recurrence, however their ability to function as biomarkers was comparable with CEA. In contrast, the combination of miR-1246, miR-1268b, and miR-4648 demonstrated a higher area under the curve (AUC) than CEA. These three miRNAs were upregulated in primary CRC tissues. Conclusion: We identified ideal combinatorial miRNAs to predict CRC recurrence.

    DOI: 10.1245/s10434-022-12355-w

    Web of Science

    Scopus

    PubMed

  • Identification of serum microRNAs as potential diagnostic biomarkers for detecting precancerous lesions of gastric cancer

    Otsu, H; Nambara, S; Hu, QJ; Hisamatsu, Y; Toshima, T; Takeishi, K; Yonemura, Y; Masuda, T; Oki, E; Mimori, K

    ANNALS OF GASTROENTEROLOGICAL SURGERY   7 ( 1 )   63 - 70   2023年1月   ISSN:2475-0328

     詳細を見る

    記述言語:英語   出版者・発行元:Annals of Gastroenterological Surgery  

    Aim: Gastric mucosal changes associated with chronic gastritis are known to be precancerous lesions of gastric cancer. We aimed to identify individuals with a high risk of gastric cancer by detection of microRNAs (miRNA) in the blood as biomarkers. Methods: Of 1206 individuals screened, 144 who were positive for Helicobacter pylori (H. pylori) by the serum antibody test and who underwent endoscopy were the subjects of this study. For the gross assessment of mucosal inflammation, we applied the Kimura–Takemoto classification, in which normal mucosa was defined as grade 0, and atrophy was categorized as grade 1 (C-1 and C-2), grade 2 (C-3 and O-1), and grade 3 (O-2 and O-3). Serum samples were divided into two phases and used for miRNA microarray profiling. We compared the expression of miRNAs in grade 3 mucosa and other grades. Expression in gastric cancer was confirmed with TCGA data. Results: miR-196b-3p was significantly upregulated, and miR-92a-2-5p was downregulated (P <.05 and q < 0.2). TCGA data showed a high expression of miR-196b-3p in gastric cancer cases (P <.001). Comparing grade 3 and the others, the area under the receiver operating characteristic curve using the detected miRNAs was as high as about 0.7. Furthermore, the combination of miRNAs resulted in higher accuracy. In terms of the significance of the combinatory mRNAs, the combination of three miRNAs (miR-196b-3p, miR-92a-2-5p, and miR-6791-3p) revealed high sensitivity and specificity, with the area under the curve exceeding 0.8. Conclusion: The identified combinatory miRNAs may represent promising biomarkers of precancerous lesions in gastric cancer.

    DOI: 10.1002/ags3.12610

    Web of Science

    Scopus

    PubMed

  • A case of malignant phyllodes tumor that responded to pazopanib and developed pneumothorax

    Ohmura, H; Masuda, T; Mimori, K; Baba, E; Horiuchi, T

    INTERNATIONAL CANCER CONFERENCE JOURNAL   12 ( 1 )   31 - 35   2023年1月   ISSN:2192-3183

     詳細を見る

  • 胃癌の前癌病変を検出するための診断バイオマーカーとなりうる血清microRNAの同定(Identification of serum microRNAs as potential diagnostic biomarkers for detecting precancerous lesions of gastric cancer)

    Otsu Hajime, Nambara Sho, Hu Qingjiang, Hisamatsu Yuichi, Toshima Takeo, Takeishi Kazuki, Yonemura Yusuke, Masuda Takaaki, Oki Eiji, Mimori Koshi

    Annals of Gastroenterological Surgery   7 ( 1 )   63 - 70   2023年1月

     詳細を見る

    記述言語:英語   出版者・発行元:John Wiley & Sons Australia, Ltd  

    本研究の目的は、血中マイクロRNA(miRNA)をバイオマーカーとして検出することで、胃癌リスクの高い症例を同定することである。スクリーニングを行った1206名のうち、血清抗体検査でヘリコバクター・ピロリ(H.pylori)陽性で、内視鏡検査を受けた144名を本研究の対象とした。粘膜炎症の肉眼的評価には、正常粘膜をグレード0、萎縮をグレード1(C-1、C-2)、グレード2(C-3、O-1)、グレード3(O-2、O-3)に分類する木村・竹本分類を適用した。血清サンプルは2相に分け、miRNAマイクロアレイプロファイリングに使用した。グレード3の粘膜とその他のグレードの粘膜におけるmiRNAの発現を比較した。胃癌における発現は、TCGAのデータで確認した。miR-196b-3pは有意に増加し、miR-92a-2-5pは減少していた(P<0.05、q<0.2)。TCGAのデータでは、胃癌症例においてmiR-196b-3pの発現が高いことが示された(P<0.001)。グレード3とそれ以外を比較すると、検出されたmiRNAを用いた受信者動作特性曲線下面積は0.7であった。さらに、miRNAを組み合わせることで、より高い精度が得られた。miRNAを組み合わせる場合、3種類のmiRNA(miR-196b-3p、miR-92a-2-5p、miR-6791-3p)の組み合わせが高い感度と特異性を示し、曲線下面積は0.8を超えていた。ここに示されたmiRNAの組み合わせは、胃癌の前癌病変のバイオマーカーとして有望である可能性がある。

  • Persistent epigenetic alterations in transcription factors after a sustained virological response in hepatocellular carcinoma

    Sugimachi, K; Araki, H; Saito, H; Masuda, T; Miura, F; Inoue, K; Shimagaki, T; Mano, Y; Iguchi, T; Morita, M; Toh, Y; Yoshizumi, T; Ito, T; Mimori, K

    JGH OPEN   6 ( 12 )   854 - 863   2022年12月   ISSN:2397-9070

     詳細を見る

    記述言語:英語   出版者・発行元:JGH Open  

    Background and Aim: The risk of hepatocellular carcinoma (HCC) persists in a condition of sustained virologic response (SVR) after hepatitis C virus (HCV) eradication. Comprehensive molecular analyses were performed to test the hypothesis that epigenetic abnormalities present after an SVR play a role in hepatocarcinogenesis. Methods: Whole-genome methylome and RNA sequencing were performed on HCV, SVR, and healthy liver tissue. Integrated analysis of the sequencing data focused on expression changes in transcription factors and their target genes, commonly found in HCV and SVR. Identified expression changes were validated in demethylated cultured HCC cell lines and an independent validation cohort. Results: The coincidence rates of the differentially methylated regions between the HCV and SVR groups were 91% in the hypomethylated and 71% in the hypermethylated regions in tumorous tissues, and 37% in the hypomethylated and 36% in the hypermethylated regions in non-tumorous tissues. These results indicate that many epigenomic abnormalities persist even after an SVR was achieved. Integrated analysis identified 61 transcription factors and 379 other genes that had methylation abnormalities and gene expression changes in both groups. Validation cohort specified gene expression changes for 14 genes, and gene ontology pathway analysis revealed apoptotic signaling and inflammatory response were associated with these genes. Conclusion: This study demonstrates that DNA methylation abnormalities, retained after HCV eradication, affect the expression of transcription factors and their target genes. These findings suggest that DNA methylation in SVR patients may be functionally important in carcinogenesis, and could serve as biomarkers to predict HCC occurrence.

    DOI: 10.1002/jgh3.12833

    Web of Science

    Scopus

    PubMed

  • Regulome-based characterization of drug activity across the human diseasome

    Iwata, M; Kosai, K; Ono, Y; Oki, S; Mimori, K; Yamanishi, Y

    NPJ SYSTEMS BIOLOGY AND APPLICATIONS   8 ( 1 )   44   2022年11月   eISSN:2056-7189

     詳細を見る

    記述言語:英語   出版者・発行元:npj Systems Biology and Applications  

    Drugs are expected to recover the cell system away from the impaired state to normalcy through disease treatment. However, the understanding of gene regulatory machinery underlying drug activity or disease pathogenesis is far from complete. Here, we perform large-scale regulome analysis for various diseases in terms of gene regulatory machinery. Transcriptome signatures were converted into regulome signatures of transcription factors by integrating publicly available ChIP-seq data. Regulome-based correlations between diseases and their approved drugs were much clearer than the transcriptome-based correlations. For example, an inverse correlation was observed for cancers, whereas a positive correlation was observed for immune system diseases. After demonstrating the usefulness of the regulome-based drug discovery method in terms of accuracy and applicability, we predicted new drugs for nonsmall cell lung cancer and validated the anticancer activity in vitro. The proposed method is useful for understanding disease–disease relationships and drug discovery.

    DOI: 10.1038/s41540-022-00255-4

    Web of Science

    Scopus

    PubMed

  • Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer

    Mochizuki, K; Kudo, S; Kato, K; Kudo, K; Ogawa, Y; Kouyama, Y; Takashina, Y; Ichimasa, K; Tobo, T; Toshima, T; Hisamatsu, Y; Yonemura, Y; Masuda, T; Miyachi, H; Ishida, F; Nemoto, T; Mimori, K

    PLOS ONE   17 ( 10 )   e0273566   2022年10月   ISSN:1932-6203

     詳細を見る

    記述言語:英語   出版者・発行元:PLoS ONE  

    Background Colorectal cancer (CRC) can be classified into four consensus molecular subtypes (CMS) according to genomic aberrations and gene expression profiles. CMS is expected to be useful in predicting prognosis and selecting chemotherapy regimens. However, there are still no reports on the relationship between the morphology and CMS. Methods This retrospective study included 55 subjects with T2 CRC undergoing surgical resection, of whom 30 had the depressed type and 25 the protruded type. In the classification of the CMS, we first defined cases with deficient mismatch repair as CMS1. And then, CMS2/3 and CMS4 were classified using an online classifier developed by Trinh et al. The staining intensity of CDX2, HTR2B, FRMD6, ZEB1, and KER and the percentage contents of CDX2, FRMD6, and KER are input into the classifier to obtain automatic output classifying the specimen as CMS2/3 or CMS4. Results According to the results yielded by the online classifier, of the 30 depressed-type cases, 15 (50%) were classified as CMS2/3 and 15 (50%) as CMS4. Of the 25 protruded-type cases, 3 (12%) were classified as CMS1 and 22 (88%) as CMS2/3. All of the T2 CRCs classified as CMS4 were depressed CRCs. More malignant pathological findings such as lymphatic invasion were associated with the depressed rather than protruded T2 CRC cases. Conclusions Depressed-type T2 CRC had a significant association with CMS4, showing more malignant pathological findings such as lymphatic invasion than the protruded-type, which could explain the reported association between CMS4 CRC and poor prognosis.

    DOI: 10.1371/journal.pone.0273566

    Web of Science

    Scopus

    PubMed

  • PRKRIP1, A Splicing Complex Factor, Is a Marker of Poor Prognosis in Colorectal Cancer

    Ozato, Y; Masuda, T; Kobayashi, Y; Takao, S; Hisamatu, Y; Toshima, T; Yonemura, Y; Uemura, M; Eguchi, H; Doki, Y; Mori, M; Mimori, K

    ANTICANCER RESEARCH   42 ( 10 )   4701 - 4706   2022年10月   ISSN:0250-7005 eISSN:1791-7530

     詳細を見る

    記述言語:英語   出版者・発行元:Anticancer Research  

    Background/Aim: Alternative splicing plays a vital role in cancer development and progression. The splicing C complex is involved in alternative splicing. However, the role of PRKR-interacting protein 1 (PRKRIP1), a component of the splicing C complex, in colorectal cancer (CRC) remains unclear. This study aimed to determine the clinicopathological, biological and prognostic significance of PRKRIP1 expression in CRC. Materials and Methods: We used a bioinformatics approach to screen for oncogenes using The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) datasets and identified PRKRIP1 as a driver gene on chromosome 7q. The mRNA expression of PRKRIP1 was measured using reverse transcription-quantitative PCR in 165 surgically resected CRC samples in our hospital, and its localization was determined using immunohistochemical staining. Gene Set Enrichment Analysis (GSEA) was performed using TCGA dataset. Results: High PRKRIP1 expression was significantly associated with poor prognosis in both the samples and TCGA dataset. A positive correlation was observed between copy number variation and PRKRIP1 expression in TCGA and CCLE datasets, and the frequency of PRKRIP1 mutations was less than 5%. Immunohistochemistry revealed that PRKRIP1 was located in the cytoplasm of tumor cells. GSEA revealed that PRKRIP1 expression was correlated with apoptosis-related gene sets. Conclusion: PRKRIP1 overexpression may be a poor prognostic biomarker for CRC. Although it is known that PRKRIP1, a spliceosome factor, is essential for splicing, we now revealed the way by which its expression accelerates CRC progression.

    DOI: 10.21873/anticanres.15974

    Web of Science

    Scopus

    PubMed

  • A case of malignant phyllodes tumor that responded to pazopanib and developed pneumothorax. 査読 国際誌

    Ohmura H, Masuda T, Mimori K, Baba E, Horiuchi T.

    Int Cancer Conf J.   12 ( 1 )   31 - 35   2022年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s13691-022-00572-9.

  • Identification of serum microRNAs as potential diagnostic biomarkers for detecting precancerous lesions of gastric cancer. 査読 国際誌

    Otsu H, Nambara S, Hu Q, Hisamatsu Y, Toshima T, Takeishi K, Yonemura Y, Masuda T, Oki E, Mimori K.

    Ann Gastroenterol Surg   7 ( 1 )   63 - 70   2022年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/ags3.12610.

  • Clinical Significance of Acylphosphatase 1 Expression in Combined HCC-iCCA, HCC, and iCCA

    Sakano, Y; Noda, T; Kobayashi, S; Kitagawa, A; Iwagami, Y; Yamada, D; Tomimaru, Y; Akita, H; Gotoh, K; Asaoka, T; Tanemura, M; Umeshita, K; Mimori, K; Doki, Y; Eguchi, H

    DIGESTIVE DISEASES AND SCIENCES   67 ( 8 )   3817 - 3830   2022年8月   ISSN:0163-2116 eISSN:1573-2568

     詳細を見る

    記述言語:英語   出版者・発行元:Digestive Diseases and Sciences  

    Background: Combined hepatocellular and cholangiocarcinoma is a rare primary liver cancer with histological features of both hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Little is known about the prognostic features and molecular mechanism of cHCC-iCCA. Acylphosphatase 1 is a cytosolic enzyme that produces acetic acid from acetyl phosphate and plays an important role in cancer progression. Aims: We evaluated the clinical significance of ACYP1 expression in cHCC-iCCA, HCC, and iCCA. Methods: ACYP1 immunohistochemistry was performed in 39 cases diagnosed with cHCC-iCCA. The prognosis was evaluated in three different cohorts (cHCC-iCCA, HCC, and iCCA). The relationships between ACYP1 expression and cell viability, migration, invasiveness, and apoptosis were examined using siRNA methods in vitro. In vivo subcutaneous tumor volumes and cell apoptosis were evaluated after downregulation of ACYP1 expression. Results: Almost half of the patients with cHCC-iCCA were diagnosed with high ACYP1 expression. In all three cohorts, the cases with high ACYP1 expression had significantly lower overall survival, and high ACYP1 expression was identified as an independent prognostic factor. Downregulation of ACYP1 reduced the proliferative capacity, migration, and invasiveness of both HCC and iCCA cells. Moreover, knockdown of ACYP1 increased the ratio of apoptotic cells and decreased the expression of anti-apoptosis proteins. In vivo tumor growth was significantly inhibited by the transfection of ACYP1 siRNA, and the number of apoptotic cells increased. Conclusion: High ACYP1 expression could influence the prognosis of cHCC-iCCA, HCC, and iCCA patients. In vitro ACYP1 expression influences the tumor growth and cell viability in both HCC and iCCA by regulating anti-apoptosis proteins.

    DOI: 10.1007/s10620-021-07266-x

    Web of Science

    Scopus

    PubMed

  • Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers

    Soyama, H; Nishio, M; Otani, J; Sakuma, T; Takao, S; Hara, S; Masuda, T; Mimori, K; Toyokuni, S; Lydon, JP; Nakao, K; Nishina, H; Fukumoto, T; Maehama, T; Suzuki, A

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   119 ( 29 )   e2123134119   2022年7月   ISSN:0027-8424 eISSN:1091-6490

     詳細を見る

    記述言語:英語   出版者・発行元:Proceedings of the National Academy of Sciences of the United States of America  

    Breast cancer is the most frequent malignancy in women worldwide. Basal-like breast cancer (BLBC) is the most aggressive form of this disease, and patients have a poor prognosis. Here, we present data suggesting that the Hippo-transcriptional coactivator with PDZ-binding motif (TAZ) pathway is a key driver of BLBC onset and progression. Deletion of Mob1a/b in mouse mammary luminal epithelium induced rapid and highly reproducible mammary tumorigenesis that was dependent on TAZ but not yes-associated protein 1 (YAP1). In situ early-stage BLBC-like malignancies developed in mutant animals by 2 wk of age, and invasive BLBC appeared by 4 wk. In a human estrogen receptor+ luminal breast cancer cell line, TAZ hyperactivation skewed the features of these luminal cells to the basal phenotype, consistent with the aberrant TAZ activation frequently observed in human precancerous BLBC lesions. TP53 mutation is rare in human precancerous BLBC but frequent in invasive BLBC. Addition of Trp53 deficiency to our Mob1a/b-deficient mouse model enhanced tumor grade and accelerated cancer progression. Our work justifies targeting the Hippo-TAZ pathway as a therapy for human BLBC, and our mouse model represents a powerful tool for evaluating candidate agents.

    DOI: 10.1073/pnas.2123134119

    Web of Science

    Scopus

    PubMed

  • Dosimetry of Occupational Eye Lens Dose Using a Novel Direct Eye Dosimeter, DOSIRIS, during Interventional Radiology Procedures

    Hirakawa, M; Nakatake, H; Tsuruta, S; Matsuura, S; Motomura, Y; Hiraki, Y; Mimori, K; Ishigami, K

    Interventional Radiology   7 ( 2 )   40 - 43   2022年7月   eISSN:24320935

     詳細を見る

    記述言語:英語   出版者・発行元:一般社団法人 日本インターベンショナルラジオロジー学会  

    DOI: 10.22575/interventionalradiology.2022-0005

    Web of Science

    PubMed

    CiNii Research

  • The Evolving Genomic Landscape of Esophageal Squamous Cell Carcinoma Under Chemoradiotherapy. 査読 国際誌

    Hirata H, Niida A, Kakiuchi N, Uchi R, Sugimachi K, Masuda T, Saito T, Kageyama SI, Motomura Y, Ito S, Yoshitake T, Tsurumaru D, Nishimuta Y, Yokoyama A, Hasegawa T, Chiba K, Shiraishi Y, Du J, Miura F, Morita M, Toh Y, Hirakawa M, Shioyama Y, Ito T, Akimoto T, Miyano S, Shibata T, Mori M, Suzuki Y, Ogawa S, Ishigami K, Mimori K.

    Cancer Res.   81 ( (19) )   4926 - 4938   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1158/0008-5472.CAN-21-0653.

  • Development of an intraoperative breast cancer margin assessment method using quantitative fluorescence measurements

    Ueo, H; Minoura, I; Ueo, H; Gamachi, A; Kai, Y; Kubota, Y; Doi, T; Yamaguchi, M; Yamashita, T; Tsuda, H; Moriya, T; Yamaguchi, R; Kozuka, Y; Sasaki, T; Masuda, T; Urano, Y; Mori, M; Mimori, K

    SCIENTIFIC REPORTS   12 ( 1 )   8520   2022年5月   ISSN:2045-2322

     詳細を見る

    記述言語:英語   出版者・発行元:Scientific Reports  

    Breast-conserving surgery has become the preferred treatment method for breast cancer. Surgical margin assessment is performed during surgery, as it can reduce local recurrence in the preserved breast. Development of reliable and lower-cost ex vivo cancer detection methods would offer several benefits for patient care. Here, a practical and quantitative evaluation method for the ex vivo fluorescent diagnosis of breast lesions was developed and confirmed through a three-step clinical study. Gamma-glutamyl-hydroxymethyl rhodamine green (gGlu-HMRG) has been reported to generate fluorescence in breast lesions. Using this probe, we constructed a reliable and reproducible procedure for the quantitative evaluation of fluorescence levels. We evaluated the reliability of the method by considering reproducibility, temperature sensitivity, and the effects of other clinicopathological factors. The results suggest that the fluorescence increase of gGlu-HMRG is a good indicator of the malignancy of breast lesions. However, the distributions overlapped. A 5 min reaction with this probe could be used to distinguish at least part of the normal breast tissue. This method did not affect the final pathological examination. In summary, our results indicate that the methods developed in this study may serve as a feasible intraoperative negative-margin assessment tool during breast-conserving surgery.

    DOI: 10.1038/s41598-022-12614-6

    Web of Science

    Scopus

    PubMed

  • Pan-cancer methylome analysis for cancer diagnosis and classification of cancer cell of origin. 査読 国際誌

    Shimizu D, Taniue K, Matsui Y, Haeno H, Araki H, Miura F, Fukunaga M, Shiraishi K, Miyamoto Y, Tsukamoto S, Komine A, Kobayashi Y, Kitagawa A, Yoshikawa Y, Sato K, Saito T, Ito S, Masuda T, Niida A, Suzuki M, Baba H, Ito T, Akimitsu N, Kodera Y, Mimori K.

    Cancer Gene Ther.   29 ( (5) )   428 - 436   2022年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1038/s41417-021-00401-w.

  • Development of an intraoperative breast cancer margin assessment method using quantitative fluorescence measurements. 査読 国際誌

    Ueo H, Minoura I, Ueo H, Gamachi A, Kai Y, Kubota Y, Doi T, Yamaguchi M, Yamashita T, Tsuda H, Moriya T, Yamaguchi R, Kozuka Y, Sasaki T, Masuda T, Urano Y, Mori M, Mimori K.

    Sci Rep.   12 ( (1) )   8520 - 8520   2022年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1038/s41598-022-12614-6.

  • Pan-cancer methylome analysis for cancer diagnosis and classification of cancer cell of origin

    Shimizu, D; Taniue, K; Matsui, Y; Haeno, H; Araki, H; Miura, F; Fukunaga, M; Shiraishi, K; Miyamoto, Y; Tsukamoto, S; Komine, A; Kobayashi, Y; Kitagawa, A; Yoshikawa, Y; Sato, K; Saito, T; Ito, S; Masuda, T; Niida, A; Suzuki, M; Baba, H; Ito, T; Akimitsu, N; Kodera, Y; Mimori, K

    CANCER GENE THERAPY   29 ( 5 )   428 - 436   2022年5月   ISSN:0929-1903 eISSN:1476-5500

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Gene Therapy  

    The accurate and early diagnosis and classification of cancer origin from either tissue or liquid biopsy is crucial for selecting the appropriate treatment and reducing cancer-related mortality. Here, we established the CAncer Cell-of-Origin (CACO) methylation panel using the methylation data of the 28 types of cancer in The Cancer Genome Atlas (7950 patients and 707 normal controls) as well as healthy whole blood samples (95 subjects). We showed that the CACO methylation panel had high diagnostic potential with high sensitivity and specificity in the discovery (maximum AUC = 0.998) and validation (maximum AUC = 1.000) cohorts. Moreover, we confirmed that the CACO methylation panel could identify the cancer cell type of origin using the methylation profile from liquid as well as tissue biopsy, including primary, metastatic, and multiregional cancer samples and cancer of unknown primary, independent of the methylation analysis platform and specimen preparation method. Together, the CACO methylation panel can be a powerful tool for the classification and diagnosis of cancer.

    DOI: 10.1038/s41417-021-00401-w

    Web of Science

    Scopus

    PubMed

  • Artificial intelligence-assisted drug repurposing via "chemical-induced gene expression ranking''

    Masuda, T; Mimori, K

    PATTERNS   3 ( 4 )   100470   2022年4月   ISSN:2666-3899

     詳細を見る

    記述言語:英語   出版者・発行元:Patterns  

    Drug repurposing using artificial intelligence algorithms is a powerful technique that leverages existing datasets to find new medical applications for approved drugs. Pham et al. developed CIGER, a deep learning framework to overcome unreliable data in the datasets and present repositioned drugs against pancreatic cancer.

    DOI: 10.1016/j.patter.2022.100470

    Web of Science

    Scopus

    PubMed

  • Artificial intelligence-assisted drug repurposing via "chemical-induced gene expression ranking". 査読 国際誌

    Masuda T, Mimori K.

    Patterns (N Y)   3 ( (4) )   100470 - 100470   2022年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1016/j.patter.2022.100470.

  • The role of Hippo-YAP1/TAZ pathway in Basal-like breast cancer

    Soyama, H; Nishio, M; Masuda, T; Mimori, K; Hara, S; Maehama, T; Fukumoto, T; Suzuki, A

    CANCER SCIENCE   113   1028 - 1028   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • The evolving genomic landscape of esophageal squamous cell carcinoma under chemoradiotherapy

    Niida, A; Hirata, H; Mimori, K

    CANCER SCIENCE   113   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • The evolving genomic landscape of esophageal squamous cell carcinoma resistant to chemoradiotherapy

    Hirata, H; Niida, A; Masuda, T; Kageyama, SI; Motomura, Y; Akimoto, T; Mimori, K

    CANCER SCIENCE   113   470 - 470   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • PRKRIP1,a factor of splicing complex, on chromosome 7q may be a novel Prognostic factors in colorectal cancer

    Ozato, Y; Masuda, T; Kobayashi, Y; Takao, S; Hisamatsu, Y; Toshima, T; Yonemura, Y; Mizushima, T; Mori, M; Eguchi, H; Doki, Y; Mimori, K

    CANCER SCIENCE   113   600 - 600   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Novel driver gene 5MP1 reprograms c-Myc translation initiation to drive malignant phenotypes in colorectal cancer

    Masuda, T; Sato, K; Koike, K; Asano, K; Mimori, K

    CANCER SCIENCE   113   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Low expression of transmembrane glycoprotein GPA33 is a poor prognostic factor in colorectal cancer.

    Abe, T; Masuda, T; Saito, H; Dairaku, K; Hashimoto, M; Nakano, Y; Hiraki, Y; Mochizuki, K; Ozato, Y; Ando, Y; Nakano, T; Koike, K; Takahashi, J; Motomura, Y; Toshima, T; Mimori, K

    CANCER SCIENCE   113   455 - 455   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • High expression of the glycolytic enzyme gene PGK1 is a prognostic factor in esophageal cancer

    Saito, H; Masuda, T; Mochizuki, K; Abe, T; Ozato, Y; Ando, Y; Nakano, T; Motomura, Y; Koike, K; Takahashi, J; Hisamatsu, Y; Toshima, T; Yonemura, Y; Saeki, H; Mimori, K

    CANCER SCIENCE   113   1196 - 1196   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • GET4 is a novel driver gene regulating the localization of BAG6 in colorectal cancer.

    Koike, K; Masuda, T; Nakano, T; Motomura, Y; Takahashi, J; Ando, Y; Toshima, T; Yonemura, Y; Nakagawa, T; Mimori, K

    CANCER SCIENCE   113   739 - 739   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Fanconi Anemia Complementation Group E, a DNA Repair-Related Gene, Is a Potential Marker of Poor Prognosis in Hepatocellular Carcinoma

    Takahashi, J; Masuda, T; Kitagawa, A; Tobo, T; Nakano, Y; Abe, T; Ando, Y; Kosai, K; Kobayashi, Y; Matsumoto, Y; Yoshizumi, T; Mori, M; Mimori, K

    ONCOLOGY   100 ( 2 )   101 - 113   2022年2月   ISSN:0030-2414 eISSN:1423-0232

     詳細を見る

    記述言語:英語   出版者・発行元:ONCOLOGY (United States)  

    Introduction: Fanconi anemia complementation group E (FANCE) is a Fanconi anemia (FA) pathway gene that regulates DNA repair. We evaluated the clinical relevance of FANCE expression in hepatocellular carcinoma (HCC). Methods: First, the associations between the expression of FA pathway genes including FANCE and clinical outcomes in HCC patients were analyzed in 2 independent cohorts: The Cancer Genome Atlas (TCGA, n = 373) and our patient cohort (n = 53). Localization of FANCE expression in HCC tissues was observed by immunohistochemical staining. Gene set enrichment analysis (GSEA) and gene network analysis (SiGN_BN) were conducted using the TCGA dataset. Next, an in vitro proliferation assay was performed using FANCE-knockdown HCC cell lines (HuH7 and HepG2). The association between mRNA expression of FANCE and that of DNA damage response genes in HCC was analyzed using TCGA and Cancer Cell Line Encyclopedia datasets. Finally, the association between FANCE mRNA expression and overall survival (OS) in various digestive carcinomas was analyzed using TCGA data. Results: FANCE was highly expressed in HCC cells. Multivariate analysis indicated that high FANCE mRNA expression was an independent factor predicting poor OS. GSEA revealed a positive relationship between enhanced FANCE expression and E2F and MYC target gene expression in HCC tissues. FANCE knockdown attenuated the proliferation of HCC cells, as well as reduced cdc25A expression and elevated histone H3 pSer10 expression. SiGN_BN revealed that FANCE mRNA expression was positively correlated with DNA damage response genes (H2A histone family member X and checkpoint kinase 1) in HCC tissues. Significant effects of high FANCE expression on OS were observed in hepatobiliary pancreatic carcinomas, including HCC. Conclusions: FANCE may provide a potential therapeutic target and biomarker of poor prognosis in HCC, possibly by facilitating tumor proliferation, which is mediated partly by cell cycle signaling activation.

    DOI: 10.1159/000520582

    Web of Science

    Scopus

    PubMed

  • FANCE, one of the Fanconi anemia (FA) pathway genes, could be a potential therapeutic target for HCC.

    Takahashi, J; Masuda, T; Kitagawa, A; Ozato, Y; Nakano, T; Kosai, K; Kobayashi, Y; Koike, K; Motomura, Y; Ando, Y; Toshima, T; Hisamatsu, Y; Yonemura, Y; Yoshizumi, T; Mimori, K

    CANCER SCIENCE   113   950 - 950   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Clinical significance of SETBP1 expression in breast cancer.

    Ando, Y; Masuda, T; Hayashi, N; Mochizuki, K; Abe, T; Saito, H; Ozato, Y; Nakano, T; Koike, K; Motomura, Y; Takahashi, J; Toshima, T; Hisamatsu, Y; Yonemura, Y; Mimori, K

    CANCER SCIENCE   113   741 - 741   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • 生活習慣病によるQOL逓減を予防するための遺伝子多型解析とIT技術を用いた地域管理システムの構築

    三森 功士

    医科学応用研究財団研究報告   39   154 - 157   2022年2月   ISSN:0914-5117

     詳細を見る

    記述言語:日本語   出版者・発行元:(公財)鈴木謙三記念医科学応用研究財団  

  • Nano-scale physical properties characteristic to metastatic intestinal cancer cells identified by high-speed scanning ion conductance microscope. 査読 国際誌

    Wang D, Sun L, Okuda S, Yamamoto D, Nakayama M, Oshima H, Saito H, Kouyama Y, Mimori K, Ando T, Watanabe S, Oshima M.

    Biomaterials.   Epub ( Epub )   Epub - Epub   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1016/j.biomaterials.2021.121256.

  • GET4 is a novel driver gene in colorectal cancer that regulates the localization of BAG6, a nucleocytoplasmic shuttling protein. 査読 国際誌

    Koike K, Masuda T, Sato K, Fujii A, Wakiyama H, Tobo T, Takahashi J, Motomura Y, Nakano T, Saito H, Matsumoto Y, Otsu H, Takeishi K, Yonemura Y, Mimori K, Nakagawa T.

    Cancer Sci.   113 ( (1) )   156 - 169   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1111/cas.15174.

  • Fanconi Anemia Complementation Group E, a DNA Repair-Related Gene, Is a Potential Marker of Poor Prognosis in Hepatocellular Carcinoma. 査読 国際誌

    Takahashi J, Masuda T, Kitagawa A, Tobo T, Nakano Y, Abe T, Ando Y, Kosai K, Kobayashi Y, Matsumoto Y, Yoshizumi T, Mori M, Mimori K.

    Oncology.   100 ( (2) )   101 - 113   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1159/000520582.

  • <i>GET4</i> is a novel driver gene in colorectal cancer that regulates the localization of BAG6, a nucleocytoplasmic shuttling protein

    Koike, K; Masuda, T; Sato, K; Fujii, A; Wakiyama, H; Tobo, T; Takahashi, J; Motomura, Y; Nakano, T; Saito, H; Matsumoto, Y; Otsu, H; Takeishi, K; Yonemura, Y; Mimori, K; Nakagawa, T

    CANCER SCIENCE   113 ( 1 )   156 - 169   2022年1月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Science  

    Colorectal cancer (CRC) is one of the most common types of cancer and a significant cause of cancer mortality worldwide. Further improvements of CRC therapeutic approaches are needed. BCL2-associated athanogene 6 (BAG6), a multifunctional scaffold protein, plays an important role in tumor progression. However, regulation of BAG6 in malignancies remains unclear. This study showed that guided entry of tail-anchored proteins factor 4 (GET4), a component of the BAG6 complex, regulates the intercellular localization of BAG6 in CRC. Furthermore, GET4 was identified as a candidate driver gene on the short arm of chromosome 7, which is often amplified in CRC, by our bioinformatics approach using the CRC dataset from The Cancer Genome Atlas. Clinicopathologic and prognostic analyses using CRC datasets showed that GET4 was overexpressed in tumor cells due to an increased DNA copy number. High GET4 expression was an independent poor prognostic factor in CRC, whereas BAG6 was mainly overexpressed in the cytoplasm of tumor cells without gene alteration. The biological significance of GET4 was examined using GET4 KO CRC cells generated with CRISPR-Cas9 technology or transfected CRC cells. In vitro and in vivo analyses showed that GET4 promoted tumor growth. It appears to facilitate cell cycle progression by cytoplasmic enrichment of BAG6-mediated p53 acetylation followed by reduced p21 expression. In conclusion, we showed that GET4 is a novel driver gene and a prognostic biomarker that promotes CRC progression by inducing the cytoplasmic transport of BAG6. GET4 could be a promising therapeutic molecular target in CRC.

    DOI: 10.1111/cas.15174

    Web of Science

    Scopus

    PubMed

  • Nano-scale physical properties characteristic to metastatic intestinal cancer cells identified by high-speed scanning ion conductance microscope

    Wang D., Sun L., Okuda S., Yamamoto D., Nakayama M., Oshima H., Saito H., Kouyama Y., Mimori K., Ando T., Watanabe S., Oshima M.

    Biomaterials   280   121256   2022年1月   ISSN:01429612

     詳細を見る

    記述言語:英語   出版者・発行元:Biomaterials  

    Recent genetic studies have indicated relationships between gene mutations and colon cancer phenotypes. However, how physical properties of tumor cells are changed by genetic alterations has not been elucidated. We examined genotype-defined mouse intestinal tumor-derived cells using a high-speed scanning ion conductance microscope (HS-SICM) that can obtain high-resolution live images of nano-scale topography and stiffness. The tumor cells used in this study carried mutations in Apc (A), Kras (K), Tgfbr2 (T), Trp53 (P), and Fbxw7 (F) in various combinations. Notably, high-metastatic cancer-derived cells carrying AKT mutations (AKT, AKTP, and AKTPF) showed specific ridge-like morphology with active membrane volume change, which was not found in low-metastatic and adenoma-derived cells. Furthermore, the membrane was significantly softer in the metastatic AKT-type cancer cells than other genotype cells. Importantly, a principal component analysis using RNAseq data showed similar distributions of expression profiles and physical properties, indicating a link between genetic alterations and physical properties. Finally, the malignant cell-specific physical properties were confirmed by an HS-SICM using human colon cancer-derived cells. These results indicate that the HS-SICM analysis is useful as a novel diagnostic strategy for predicting the metastatic ability of cancer cells.

    DOI: 10.1016/j.biomaterials.2021.121256

    Scopus

    PubMed

  • GET4遺伝子は大腸癌の新規ドライバー遺伝子であり、核-細胞質間輸送にかかわる蛋白質であるBAG6の局在を調節する(GET4 is a novel driver gene in colorectal cancer that regulates the localization of BAG6, a nucleocytoplasmic shuttling protein)

    Koike Kensuke, Masuda Takaaki, Sato Kuniaki, Fujii Atsushi, Wakiyama Hiroaki, Tobo Taro, Takahashi Junichi, Motomura Yushi, Nakano Takafumi, Saito Hideyuki, Matsumoto Yoshihiro, Otsu Hajime, Takeishi Kazuki, Yonemura Yusuke, Mimori Koshi, Nakagawa Takashi

    Cancer Science   113 ( 1 )   156 - 169   2022年1月   ISSN:1347-9032

     詳細を見る

    記述言語:英語   出版者・発行元:John Wiley & Sons Australia, Ltd  

    BCL2関連athanogene 6(BAG6)複合体の構成要素であるguided entry of tail-anchored proteins factor 4(GET4)が、大腸癌においてBAG6の細胞内局在を制御していることを明らかにした。癌ゲノムデータベースのデータセットを解析したところ、大腸癌でGET4遺伝子はしばしば増幅しており、ドライバー遺伝子の候補となることが突き止められた。GET4遺伝子は腫瘍細胞でDNAコピー数が増加しているために過剰発現していることが判明し、GET4高発現は予後不良の独立因子となっていた。BAG6には遺伝子変化が認められ、主に腫瘍細胞の細胞質内で過剰発現していた。大腸癌細胞を用いたノックアウト実験によってGET4の生物学的重要性について検討した。その結果、in vitro、in vivoのいずれでもGET4は腫瘍の増殖を促進することが示された。BAG6が媒介するp53のアセチル化が細胞質内で豊富に生じ、次いでp21発現が減少するために細胞周期の進行が促進されていると思われた。以上から、GET4はBAG6の細胞質移行を誘導して大腸癌の進行を促進する新規ドライバー遺伝子であり、予後バイオマーカーにもなることが明らかになった。

  • バイオマーカーとなり得る解糖系関連遺伝子の探索

    斉藤 秀幸, 細田 清孝, 大楽 勝司, 中野 祐輔, 橋本 雅弘, 平木 嘉樹, 阿部 正, 安東 由貴, 本村 有史, 久松 雄一, 戸島 剛男, 米村 祐輔, 増田 隆明, 佐伯 浩司, 三森 功士

    日本分子腫瘍マーカー研究会誌   38 ( 0 )   24 - 25   2022年   eISSN:24338575

     詳細を見る

    記述言語:日本語   出版者・発行元:日本分子腫瘍マーカー研究会  

    DOI: 10.11241/jsmtmr.38.24

    CiNii Research

  • I.大腸がんにおける分子標的療法の適応となるゲノム異常(総論)

    三森 功士

    日本大腸肛門病学会雑誌   75 ( 10 )   449 - 452   2022年   ISSN:00471801 eISSN:18829619

     詳細を見る

    記述言語:日本語   出版者・発行元:日本大腸肛門病学会  

    <p>がんゲノム医療により分子標的薬に合致した患者群は生存期間が延長した.しかしその恩恵を享受できる症例は未だに少ない.ごく最近,ミスマッチ修復酵素異常を有する直腸がん12例に対してPD1阻害剤を投与したところComplete Responseが100%という衝撃的な報告がなされたことをまず紹介する.一般に大腸がんはAPC/βcateninなどWNTシグナル経路,KRASを擁するEGFR/PI3Kシグナル経路,Notchシグナル経路そしてTGFβシグナル経路におけるゲノム変異が重要であり,これらを標的とした創薬において世界中で鎬が削られている.また核内転写因子に対する阻害剤の開発は難しいとされておりWnt/βcatenin TCF複合体に対しては未だに有効な化合物はない.本稿では免疫療法を含め大腸がん治療標的となる遺伝子変異を改めて確認すると同時に治療薬に関する最新情報の一部を紹介する.</p>

    DOI: 10.3862/jcoloproctology.75.449

    CiNii Research

  • Clinical Significance of Acylphosphatase 1 Expression in Combined HCC-iCCA, HCC, and iCCA. 査読 国際誌

    Sakano Y, Noda T, Kobayashi S, Kitagawa A, Iwagami Y, Yamada D, Tomimaru Y, Akita H, Gotoh K, Asaoka T, Tanemura M, Umeshita K, Mimori K, Doki Y, Eguchi H.

    Dig Dis Sci.   Epub ( Epub )   Epub - Epub   2021年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1007/s10620-021-07266-x.

  • Postoperative elevation in the plasma CCL2 level is a predictive biomarker of colorectal cancer recurrence. 査読 国際誌

    Fukunaga M, Mimori K, Masuda T, Hu Q, Yamada K, Mori M.

    Surg Today.   51 ( (10) )   1671 - 1681   2021年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1007/s00595-021-02273-x.

  • Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA. 査読 国際誌

    Sunami K, Bando H, Yatabe Y, Naito Y, Takahashi H, Tsuchihara K, Toyooka S,Mimori K, Kohsaka S, Uetake H, Kinoshita I, Komine K, Takeda M, Hayashida T, Tamura K, Nishio K, Yamamoto N; Working Group of a Joint Task Force of Three Academic Societies for the Promotion of Cancer Genomic Medicine.

    Cancer Sci.   112 ( (9) )   3911 - 3917   2021年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1111/cas.15022.

  • Successful Treatment with Hepatic Arterial Infusion Chemotherapy in a Breast Cancer Patient with Multiple Liver Metastases Who Declined Systemic Therapy. 査読 国際誌

    Masuda T, Niizeki O, Niizeki T, Fujiyoshi K, Ando Y, Niizeki H, Mimori K.

    Case Rep Oncol.   14 ( (3) )   1261 - 1265   2021年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1159/000517854.

  • Single-cell DNA and RNA sequencing reveals the dynamics of intra-tumor heterogeneity in a colorectal cancer model. 査読 国際誌

    Ono H, Arai Y, Furukawa E, Narushima D, Matsuura T, Nakamura H, Shiokawa D, Nagai M, Imai T, Mimori K, Okamoto K, Hippo Y, Shibata T, Kato M.

    BMC Biol.   19 ( (1) )   207 - 207   2021年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1186/s12915-021-01147-5.

  • Radiology- and gene-based risk stratification in small renal cell carcinoma: A preliminary study. 査読 国際誌

    Takao S, Ushijima Y, Motomura Y, Sakamoto K, Hirakawa M, Nishie A, Mimori K, Yamashita Y, Tsutsumi T, Ishigami K.

    PLoS One.   16 ( (9) )   e0256471 - e0256471   2021年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1371/journal.pone.0256471.

  • Oxysterol binding protein-like 3 (OSBPL3) is a novel driver gene that promotes tumor growth in part through R-Ras/Akt signaling in gastric cancer. 査読 国際誌

    Hu Q, Masuda T, Koike K, Sato K, Tobo T, Kuramitsu S, Kitagawa A, Fujii A, Noda M, Tsuruda Y, Otsu H, Kuroda Y, Ito S, Oki E, Mimori K.

    Sci Rep.   11 ( (1) )   19178 - 19178   2021年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1038/s41598-021-98485-9.

  • Cancer-associated Fibroblast-derived Spondin-2 Promotes Motility of Gastric Cancer Cells. 査読 国際誌

    Kuramitsu S, Masuda T, Hu Q, Tobo T, Yashiro M, Fujii A, Kitagawa A, Abe T, Otsu H, Ito S, Oki E, Mori M, Mimori K.

    Cancer Genomics Proteomics.   18 ( (4) )   521 - 529   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.21873/cgp.20277.

  • Potential association of LOXL1 with peritoneal dissemination in gastric cancer possibly via promotion of EMT. 査読 国際誌

    Hu Q, Masuda T, Kuramitsu S, Tobo T, Sato K, Kidogami S, Nambara S, Ueda M, Tsuruda Y, Kuroda Y, Ito S, Oki E, Mori M, Mimori K.

    PLoS One   159 ( 10 )   e0241140.   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1371/journal.pone.0241140.

  • Reduction of T-Box 15 gene expression in tumor tissue is a prognostic biomarker for patients with hepatocellular carcinoma. 招待 査読 国際誌

    Morine Y, Utsunomiya T, Saito Y, Yamada S, Imura S, Ikemoto T, Kitagawa A, Kobayashi Y, Takao S, Kosai K, Mimori K, Tanaka Y, Shimada M.

    Oncotarget   11 ( 52 )   4803 - 4812   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.18632/oncotarget.27852.

  • Modeling colorectal cancer evolution. 査読 国際誌

    Niida A, Mimori K, Shibata T, Miyano S.

    J Hum Genet   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s10038-021-00930-0.

  • Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer. 査読 国際誌

    Hu Q, Nonaka K, Wakiyama H, Miyashita Y, Fujimoto Y, Jogo T, Hokonohara K, Nakanishi R, Hisamatsu Y, Ando K, Kimura Y, Masuda T, Oki E, Mimori K, Oda Y, Mori M.

    Cancer Med   10 ( 9 )   3129 - 3138   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/cam4.3828.

  • Mitotic checkpoint regulator RAE1 promotes tumor growth in colorectal cancer. 査読 国際誌

    Kobayashi Y, Masuda T, Fujii A, Shimizu D, Sato K, Kitagawa A, Tobo T, Ozato Y, Saito H, Kuramitsu S, Noda M, Otsu H, Mizushima T, Doki Y, Eguchi H, Mori M, Mimori K.

    Cancer Sci   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.14969.

  • The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer. 査読 国際誌

    Fujii A, Masuda T, Iwata M, Tobo T, Wakiyama H, Koike K, Kosai K, Nakano T, Kuramitsu S, Kitagawa A, Sato K, Kouyama Y, Shimizu D, Matsumoto Y, Utsunomiya T, Ohtsuka T, Yamanishi Y, Nakamura M, Mimori K.

    Cancer Sci   112 ( 4 )   1655 - 1668   2021年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.14858.

  • Postoperative elevation in the plasma CCL2 level is a predictive biomarker of colorectal cancer recurrence. 査読 国際誌

    Fukunaga M, Mimori K, Masuda T, Hu Q, Yamada K, Mori M.

    Surg Today   2021年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00595-021-02273-x.

  • Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases 査読 国際誌

    Sakimura S, Nagayama S, Fukunaga M, Hu Q, Kitagawa A, Kobayashi Y, Hasegawa T, Noda M, Kouyama Y, Shimizu D, Saito T, Niida A, Tsuruda Y, Otsu H, Matsumoto Y, Uchida H, Masuda T, Sugimachi K, Sasaki S, Yamada K, Takahashi K, Innan H, Suzuki Y, Nakamura H, Totoki Y, Mizuno S, Ohshima M, Shibata T, Mimori K.

    17 ( (1) )   e1009113. - e1009113.   2021年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1371/journal.pgen.

  • Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases. 査読 国際誌

    Sakimura S, Nagayama S, Fukunaga M, Hu Q, Kitagawa A, Kobayashi Y, Hasegawa T, Noda M, Kouyama Y, Shimizu D, Saito T, Niida A, Tsuruda Y, Otsu H, Matsumoto Y, Uchida H, Masuda T, Sugimachi K, Sasaki S, Yamada K, Takahashi K, Innan H, Suzuki Y, Nakamura H, Totoki Y, Mizuno S, Ohshima M, Shibata T, Mimori K.

    PLoS Genet   17 ( 1 )   e1009113.   2021年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1371/journal.pgen.1009113.

  • Depressed Colorectal Cancer: A New Paradigm in Early Colorectal Cancer. 査読 国際誌

    Kudo SE, Kouyama Y, Ogawa Y, Ichimasa K, Hamada T, Kato K, Kudo K, Masuda T, Otsu H, Misawa M, Mori Y, Kudo T, Hayashi T, Wakamura K, Miyachi H, Sawada N, Sato T, Shibata T, Hamatani S, Nemoto T, Ishida F, Niida A, Miyano S, Oshima M, Ogino S, Mimori K.

    Clin Transl Gastroenterol.   11 ( 12 )   e00269.   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.14309/ctg.0000000000000269.

  • The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. 査読 国際誌

    Chen B, Dragomir MP, Fabris L, Bayraktar R, Knutsen E, Liu X, Tang C, Li Y,Shimura T, Ivkovic TC, Cruz De Los Santos M, Anfossi S, Shimizu M, Shah MY, Ling H, Shen P, Multani AS, Pardini B, Burks JK, Katayama H, Reineke LC, Huo L, Syed M, Song S, Ferracin M, Oki E, Fromm B, Ivan C, Bhuvaneshwar K, Gusev Y, Mimori K, Menter D, Sen S, Matsuyama T, Uetake H, Vasilescu C, Kopetz S, Parker-Thornburg J, Taguchi A, Hanash SM, Girnita L, Slaby O, Goel A, Varani G, Gagea M, Li C, Ajani JA, Calin GA.

    Gastroenterology   159 ( 6 )   2146 - 2162   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1053/j.gastro.2020.08.018.

  • A case of a patient receiving combination therapy with paclitaxel plus bevacizumab and adoptive activated αβ T-cell immunotherapy in advanced breast cancer. 査読 国際誌

    26 ( 12 )   2420 - 2423   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/tbj.14108

  • miR-221 Targets QKI to Enhance the Tumorigenic Capacity of Human Colorectal Cancer Stem Cells. 査読 国際誌

    Mukohyama J, Isobe T, Hu Q, Hayashi T, Watanabe T, Maeda M, Yanagi H, Qian X, Yamashita K, Minami H, Mimori K, Sahoo D, Kakeji Y, Suzuki A, Dalerba P, Shimono Y.

    Cancer Res.   79 ( 20 )   5151 - 5158   2020年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1158/0008-5472.CAN-18-3544.

  • The Expression Level of PD-L1 (CD274) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer. 査読 国際誌

    Masuda T, Noda M, Kitagawa A, Hu Q, Fujii A, Ito S, Kosai K, Ando Y, Matsumoto Y, Ohtsu H, Uchida H, Ohno S, Mimori K.

    Anticancer Res.   40 ( 7 )   3733 - 3742   2020年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/anticanres.14362.

  • YAP1 Activation Drives Immediate Onset of Cervical Carcinoma In Situ in Mice. 査読 国際誌

    Nishio M, To Y, Maehama T, Aono Y, Otani J, Hikasa H, Kitagawa A, Mimori K, Sasaki T, Nishina H, Toyokuni S, Lydon JP, Nakao K, Wah Mak T, Kiyono T, Katabuchi H, Tashiro H, Suzuki A.

    Cancer Sci.   Epub ( Epub )   Epub   2020年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.14581.

  • Genetic landscape of external auditory canal squamous cell carcinoma. 査読 国際誌

    Sato K, Komune N, Hongo T, Koike K, Niida A, Uchi R, Noda T, Kogo R, Matsumoto N, Yamamoto H, Masuda M, Oda Y, Mimori K, Nakagawa T.

    Cancer Sci.   Epub ( Epub )   Epub   2020年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.14515.

  • F3B4 Plays an Oncogenic Role in Esophageal Squamous Cell Carcinoma. 査読 国際誌

    Kidogami S, Iguchi T, Sato K, Yoshikawa Y, Hu Q, Nambara S, Komatsu H, Ueda M, Kuroda Y, Masuda T, Mori M, Doki Y, Mimori K.

    Anticancer Res.   40 ( 5 )   2941 - 2946   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/anticanres.14272.

  • Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer. 査読 国際誌

    Ito S, Masuda T, Noda M, Hu Q, Shimizu D, Kuroda Y, Eguchi H, Tobo T, Utsunomiya T, Mimori K.

    Oncology.   98 ( 7 )   501 - 511   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1159/000506075.

  • Drug repositioning in cancer: The current situation in Japan. 査読 国際誌

    Masuda T, Tsuruda Y, Matsumoto Y, Uchida H, Nakayama KI, Mimori K.

    Cancer Sci.   111 ( 4 )   1039 - 1046   2020年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.14318.

  • A unified simulation model for understanding the diversity of cancer evolution. 査読 国際誌

    Niida A, Hasegawa T, Innan H, Shibata T, Mimori K, Miyano S.

    PeerJ.   8   e8842.   2020年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.7717/peerj.8842.

  • YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma. 査読 国際誌

    Omori H, Nishio M, Masuda M, Miyachi Y, Ueda F, Nakano T, Sato K, Mimori K, Taguchi K, Hikasa H, Nishina H, Tashiro H, Kiyono T, Mak TW, Nakao K, Nakagawa T, Maehama T, Suzuki A.

    Sci Adv.   6 ( 12 )   eaay3324   2020年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1126/sciadv.aay3324.

  • KIF15 Expression in Tumor-associated Monocytes Is a Prognostic Biomarker in Hepatocellular Carcinoma. 査読 国際誌

    Kitagawa A, Masuda T, Takahashi J, Tobo T, Noda M, Kuroda Y, Hu Q, Kouyama Y, Kobayashi Y, Kuramitsu S, Sato K, Fujii A, Yoshikawa Y, Wakiyama H, Shimizu D, Tsuruda Y, Eguchi H, Doki Y, Mori M, Mimori K.

    Cancer Genomics Proteomics.   17 ( 2 )   141 - 149   2020年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/cgp.20174.

  • Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients. 査読 国際誌

    Noda M, Masuda T, Ito S, Tobo T, Kitagawa A, Hu Q, Shimizu D, Eguchi H, Etoh T, Ohno S, Inomata M, Mimori K.

    Ann Surg Oncol.   Epub ( Epub )   Epub   2020年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-020-08375-z.

  • Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer. 査読 国際誌

    Masuda T, Noda M, Kogawa T, Kitagawa D, Hayashi N, Jomori T, Nakanishi Y, Nakayama KI, Ohno S, Mimori K.

    Cancer Sci.   111 ( 3 )   924 - 931   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.14306.

  • GTF2IRD1 on chromosome 7 is a novel oncogene regulating the tumor-suppressor gene TGFβR2 in colorectal cancer. 査読 国際誌

    111 ( 2 )   343 - 355   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.14248.

  • N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study. 査読 国際誌

    Masuda T, Ueo H, Kai Y, Noda M, Hu Q, Sato K, Fujii A, Hayashi N, Tsuruda Y, Otsu H, Kuroda Y, Eguchi H, Ohno S, Mimori K, Ueo H.

    Int J Mol Sci.   21 ( 2 )   511   2020年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3390/ijms21020511.

  • ARL4C and Peritoneal Dissemination in Gastric Cancer. 査読 国際誌

    Hu Q, Mimori K.

    Ann Surg Oncol.   26 ( Suppl 3 )   547   2019年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-018-7056-7.

  • Oncogenic splicing abnormalities induced by DEAD-Box Helicase 56 amplification in colorectal cancer. 査読 国際誌

    Kouyama Y, Masuda T, Fujii A, Ogawa Y, Sato K, Tobo T, Wakiyama H, Yoshikawa Y, Noda M, Tsuruda Y, Kuroda Y, Eguchi H, Ishida F, Kudo SE, Mimori K.

    Cancer Sci.   110 ( 10 )   3132 - 3144   2019年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.14163.

  • Distinct methylation levels of mature microRNAs in gastrointestinal cancers. 査読 国際誌

    Konno M, Koseki J, Asai A, Yamagata A, Shimamura T, Motooka D, Okuzaki D, Kawamoto K, Mizushima T, Eguchi H, Takiguchi S, Satoh T, Mimori K, Ochiya T, Doki Y, Ofusa K, Mori M, Ishii H.

    Nat Commun.   10 ( (1) )   3888   2019年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41467-019-11826-1.

  • Novel oncogene 5MP1 reprograms c-Myc translation initiation to drive malignant phenotypes in colorectal cancer. 査読 国際誌

    Sato K, Masuda T, Hu Q, Tobo T, Gillaspie S, Niida A, Thornton M, Kuroda Y, Eguchi H, Nakagawa T, Asano K, Mimori K.

    EBioMedicine.   S2352-3964(19)30366-4.   2019年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.ebiom.

  • Preventive and promotive effects of habitual hot spa-bathing on the elderly in Japan. 査読 国際誌

    Maeda T, Mimori K, Suzuki S, Horiuchi T, Makino N.

    Sci Rep.   8 ( 1 )   133   2019年6月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41598-017-18488-3.

  • Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens. 査読 国際誌

    Kohsaka S, Tatsuno K, Ueno T, Nagano M, Shinozaki-Ushiku A, Ushiku T, Takai D, Ikegami M, Kobayashi H, Kage H, Ando M, Hata K, Ueda H, Yamamoto S, Kojima S,Oseto K, Akaike K, Suehara Y, Hayashi T, Saito T, Takahashi F, Takahashi K,Takamochi K, Suzuki K, Nagayama S, Oda Y, Mimori K, Ishihara S, Yatomi Y, NagaseT, Nakajima J, Tanaka S, Fukayama M, Oda K, Nangaku M, Miyazono K, Miyagawa K,Aburatani H, Mano H.

    Cancer Sci.   110 ( 4 )   1464 - 1479   2019年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.13968.

  • Disruption of FBXL5-mediated cellular iron homeostasis promotes liver carcinogenesis. 査読 国際誌

    Muto Y, Moroishi T, Ichihara K, Nishiyama M, Shimizu H, Eguchi H, Moriya K, Koike K, Mimori K, Mori M, Katayama Y, Nakayama KI.

    Cancer Sci.   2019年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.14075.

  • Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents. 査読 国際誌

    Yumimoto K, Sugiyama S, Mimori K, Nakayama KI.

    Cancer Sci.   2019年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.14075.

  • Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens. 査読 国際誌

    Kohsaka S, Tatsuno K, Ueno T, Nagano M, Shinozaki-Ushiku A, Ushiku T, Takai D, Ikegami M, Kobayashi H, Kage H, Ando M, Hata K, Ueda H, Yamamoto S, Kojima S, Oseto K, Akaike K, Suehara Y, Hayashi T, Saito T, Takahashi F, Takahashi K, Takamochi K, Suzuki K, Nagayama S, Oda Y, Mimori K, Ishihara S, Yatomi Y, Nagase T, Nakajima J, Tanaka S, Fukayama M, Oda K, Nangaku M, Miyazono K, Miyagawa K, Aburatani H, Mano H.

    Cancer Sci.   110 ( 4 )   1464 - 1479   2019年4月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.13968.

  • A clinical trial of somatic and germline analyses for healthy longevity in a postoperative cancer patient. 査読 国際誌

    Hayashi N, Kuroda Y, Saito T, Tsuruda Y, Niida A, Otsu H, Eguchi H, Masuda T, Suzuki Y, Natsugoe S, Mimori K.

    Surg Today.   2019年3月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00595-019-01789-7.

  • Plastin3 is associated with epithelial-mesenchymal transition and poor prognosis in gastric cancer. 査読 国際誌

    Kurashige J, Yokobori T, Mima K, Sawada G, Takahashi Y, Ueo H, Takano Y, Matsumura T, Uchi R, Eguchi H, Sudo T, Sugimachi K, Mori M, Baba H, Mimori K.

    Oncol Lett.   17 ( 2 )   2393 - 2399   2019年2月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/ol.2018.9819.

  • Age-related remodelling of oesophageal epithelia by mutated cancer drivers. 査読 国際誌

    Yokoyama A, Kakiuchi N, Yoshizato T, Nannya Y, Suzuki H, Takeuchi Y, Shiozawa Y, Sato Y, Aoki K, Kim SK, Fujii Y, Yoshida K, Kataoka K, Nakagawa MM, Inoue Y, Hirano T, Shiraishi Y, Chiba K, Tanaka H, Sanada M, Nishikawa Y, Amanuma Y, Ohashi S, Aoyama I, Horimatsu T, Miyamoto S, Tsunoda S, Sakai Y, Narahara M, Brown JB, Sato Y, Sawada G, Mimori K, Minamiguchi S, Haga H, Seno H, Miyano S, Makishima H, Muto M, Ogawa S.

    Nature.   565 ( 7739 )   312 - 317   2019年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41586-018-0811-x.

  • Multiregion Genomic Analysis of Serially Transplanted Patient-derived Xenograft Tumors. 査読 国際誌

    Sato K, Niida A, Masuda T, Shimizu D, Tobo T, Kuroda Y, Eguchi H, Nakagawa T, Suzuki Y, Mimori K.

    Cancer Genomics Proteomics.   16 ( 1 )   21 - 27   2019年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/cgp.20109.

  • CRMP5-associated GTPase (CRAG) Is a Candidate Driver Gene for Colorectal Cancer Carcinogenesis. 査読 国際誌

    Shimizu D, Masuda T, Sato K, Tsuruda Y, Otsu H, Kuroda Y, Eguchi H, Kodera Y, Mimori K.

    Anticancer Res.   39 ( 1 )   99 - 106   2019年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/anticanres.13084.

  • Preventive and promotive effects of habitual hot spa-bathing on the elderly in Japan 査読

    Toyoki Maeda, Koshi Mimori, Sadao Suzuki, Takahiko Horiuchi, Naoki Makino

    Scientific Reports   8 ( 1 )   2018年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41598-017-18488-3

  • Cytolytic Activity (CYT) Score Is a Prognostic Biomarker Reflecting Host Immune Status in Hepatocellular Carcinoma (HCC). 査読 国際誌

    Wakiyama H, Masuda T, Motomura Y, Hu Q, Tobo T, Eguchi H, Sakamoto K, Hirakawa M, Honda H, Mimori K.

    Anticancer Res.   38 ( 12 )   6631 - 6638   2018年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/anticanres.13030.

  • Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients. 査読 国際誌

    Ito S, Fukagawa T, Noda M, Hu Q, Nambara S, Shimizu D, Kuroda Y, Eguchi H, Masuda T, Sato T, Katai H, Sasako M, Mimori K.

    Ann Surg Oncol.   25 ( 12 )   3755 - 3763   2018年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-018-6739-4.

  • Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy. 査読 国際誌

    Sugimachi K, Sakimura S, Kuramitsu S, Hirata H, Niida A, Iguchi T, Eguchi H, Masuda T, Morita M, Toh Y, Maehara Y, Suzuki Y, Mimori K.

    Br J Cancer.   119 ( 4 )   419 - 423   2018年8月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41416-018-0208-5.

  • Circulating Pre-microRNA-488 in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer. 査読 国際誌

    Masuda T, Shinden Y, Noda M, Ueo H, Hu Q, Yoshikawa Y, Tsuruda Y, Kuroda Y, Ito S, Eguchi H, Ohno S, Mimori K.

    Anticancer Res.   38 ( 8 )   4515 - 4523   2018年8月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/anticanres.12755.

  • Cancer evolution and heterogeneity. 査読 国際誌

    Mimori K, Saito T, Niida A, Miyano S.

    Ann Gastroenterol Surg.   2 ( 5 )   332 - 338   2018年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/ags3.12182.

  • Overexpression of FGFR1 Promotes Peritoneal Dissemination Via Epithelial-to-Mesenchymal Transition in Gastric Cancer. 査読 国際誌

    Shimizu D, Saito T, Ito S, Masuda T, Kurashige J, Kuroda Y, Eguchi H, Kodera Y, Mimori K.

    Cancer Genomics Proteomics.   15 ( 4 )   313 - 320   2018年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/cgp.20089.

  • A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer. 査読 国際誌

    Saito T, Niida A, Uchi R, Hirata H, Komatsu H, Sakimura S, Hayashi S, Nambara S, Kuroda Y, Ito S, Eguchi H, Masuda T, Sugimachi K, Tobo T, Nishida H, Daa T, Chiba K, Shiraishi Y, Yoshizato T, Kodama M, Okimoto T, Mizukami K, Ogawa R, Okamoto K, Shuto M, Fukuda K, Matsui Y, Shimamura T, Hasegawa T, Doki Y, Nagayama S, Yamada K, Kato M, Shibata T, Mori M, Aburatani H, Murakami K, Suzuki Y, Ogawa S, Miyano S, Mimori K.

    Nat Commun.   9 ( 1 )   2884   2018年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41467-018-05226-0.

  • GWAS identifies two novel colorectal cancer loci at 16q24.1 and 20q13.12. 査読 国際誌

    Tanikawa C, Kamatani Y, Takahashi A, Momozawa Y, Leveque K, Nagayama S, Mimori K, Mori M, Ishii H, Inazawa J, Yasuda J, Tsuboi A, Shimizu A, Sasaki M, Yamaji T, Sawada N, Iwasaki M, Tsugane S, Naito M, Wakai K, Koyama T, Takezaki T, Yuji K, Murakami Y, Nakamura Y, Kubo M, Matsuda K.

    Carcinogenesis.   39 ( 5 )   652 - 660   2018年5月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/carcin/bgy026.

  • Understanding intratumor heterogeneity by combining genome analysis and mathematical modeling. 査読 国際誌

    Niida A, Nagayama S, Miyano S, Mimori K.

    Cancer Sci.   109 ( 4 )   884 - 892   2018年4月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.13510.

  • Understanding intratumor heterogeneity by combining genome analysis and mathematical modeling 査読

    Atsushi Niida, Satoshi Nagayama, Satoru Miyano, Koshi Mimori

    Cancer Science   109 ( 4 )   884 - 892   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.13510

  • Combined mutation of Apc, Kras, and Tgfbr2 effectively drives metastasis of intestinal cancer 査読

    Eri Sakai, Mizuho Nakayama, Hiroko Oshima, Yuta Kouyama, Atsushi Niida, Satoshi Fujii, Atsushi Ochiai, Keiichi Nakayama, Koshi Mimori, Yutaka Suzuki, Chang Pyo Hong, Chan Young Ock, Seong Jin Kim, Masanobu Oshima

    Cancer Research   78 ( 5 )   1334 - 1346   2018年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1158/0008-5472.CAN-17-3303

  • Identification of ARL4C as a Peritoneal Dissemination-Associated Gene and Its Clinical Significance in Gastric Cancer 査読

    Qingjiang Hu, Takaaki Masuda, Kuniaki Sato, Taro Tobo, Sho Nambara, Shinya Kidogami, Naoki Hayashi, Yohsuke Kuroda, Shuhei Ito, Hidetoshi Eguchi, Hiroshi Saeki, Eiji Oki, Yoshihiko Maehara, Koshi Mimori

    Annals of Surgical Oncology   25 ( 3 )   745 - 753   2018年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-017-6292-6

  • PLOD2 as a potential regulator of peritoneal dissemination in gastric cancer 査読

    Yuki Kiyozumi, Masaaki Iwatsuki, Junji Kurashige, Yoko Ogata, Kohei Yamashita, Yuki Koga, Tasuku Toihata, Yukiharu Hiyoshi, Takatsugu Ishimoto, Yoshifumi Baba, Yuji Miyamoto, Naoya Yoshida, Kazuyoshi Yanagihara, Koshi Mimori, Hideo Baba

    International Journal of Cancer   2018年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/ijc.31410

  • Clinicopathological characteristics of disseminated carcinomatosis of the bone marrow in breast cancer patients. 査読 国際誌

    Shinden Y, Sugimachi K, Tanaka F, Fujiyoshi K, Kijima Y, Natsugoe S, Mimori K.

    Mol Clin Oncol.   8 ( 1 )   93 - 98   2018年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/mco.2017.1502.

  • Identification of UHRF2 as a Negative Regulator of Epithelial-Mesenchymal Transition and Its Clinical Significance in Esophageal Squamous Cell Carcinoma. 査読 国際誌

    Iguchi T, Ueda M, Masuda T, Nambara S, Kidogami S, Komatsu H, Sato K, Tobo T, Ogawa Y, Hu Q, Saito T, Hirata H, Sakimura S, Uchi R, Hayashi N, Ito S, Eguchi H, Sugimachi K, Maehara Y, Mimori K.

    Oncology.   5 ( 3 )   179 - 187   2018年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1159/000488860.

  • Long-term outcome of adipose-derived regenerative cell-enriched autologous fat transplantation for reconstruction after breast-conserving surgery for Japanese women with breast cancer 査読

    Shuhei Ito, Yuichiro Kai, Takaaki Masuda, Fumiaki Tanaka, Toshifumi Matsumoto, Yukio Kamohara, Hiroshi Hayakawa, Hiroaki Ueo, Hideki Iwaguro, Marc H. Hedrick, Koshi Mimori, Masaki Mori

    Surgery Today   47 ( 12 )   1500 - 1511   2017年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00595-017-1544-4

  • Japanese genome-wide association study identifies a significant colorectal cancer susceptibility locus at chromosome 10p14 査読

    Yusuke Takahashi, Keishi Sugimachi, Ken Yamamoto, Atsushi Niida, Teppei Shimamura, Tetsuya Sato, Masahiko Watanabe, Junichi Tanaka, Shinei Kudo, Kenichi Sugihara, Kazuo Hase, Masato Kusunoki, Kazutaka Yamada, Yasuhiro Shimada, Yoshihiro Moriya, Yutaka Suzuki, Satoru Miyano, Masaki Mori, Koshi Mimori

    Cancer Science   108 ( 11 )   2239 - 2247   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.13391

  • Clinical Impact of Tumor-Infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma 査読

    Tomoya Sudo, Ryosuke Nishida, Akihiko Kawahara, Kouhei Saisho, Koshi Mimori, Akira Yamada, Atsuhi Mizoguchi, Kazutaka Kadoya, Satoru Matono, Naoki Mori, Toshiaki Tanaka, Yoshito Akagi

    Annals of Surgical Oncology   24 ( 12 )   3763 - 3770   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-017-5796-4

  • Diagnostic laparoscopy for pneumatosis intestinalis in a very elderly patient A case report 査読

    Shuhei Ito, Takaaki Masuda, Noboru Harada, Ayumi Matsuyama, Motoharu Hamatake, Takashi Maeda, Shinichi Tsutsui, Hiroyuki Matsuda, Koshi Mimori, Teruyoshi Ishida

    Annals of Medicine and Surgery   21   109 - 113   2017年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.amsu.2017.07.058

  • MicroRNAs as biomarkers in colorectal cancer 査読

    Takaaki Masuda, Naoki Hayashi, Yohsuke Kuroda, Shuhei Ito, Hidetoshi Eguchi, Koshi Mimori

    Cancers   9 ( 9 )   2017年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3390/cancers9090124

  • Altered Expression of Hippo Signaling Pathway Molecules in Intrahepatic Cholangiocarcinoma 査読

    Keishi Sugimachi, Miki Nishio, Shinichi Aishima, Yohsuke Kuroda, Tomohiro Iguchi, Hisateru Komatsu, Hidenari Hirata, Shotaro Sakimura, Hidetoshi Eguchi, Yuki Bekki, Kenji Takenaka, Yoshihiko Maehara, Akira Suzuki, Koshi Mimori

    Oncology   93 ( 1 )   67 - 74   2017年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1159/000463390

  • Overexpression of CXCR7 Is a novel prognostic indicator in gastric cancer 査読

    Sho Nambara, Tomohiro Iguchi, Eiji Oki, Patrick Tan, Yoshihiko Maehara, Koshi Mimori

    Digestive Surgery   34 ( 4 )   312 - 318   2017年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1159/000452977

  • MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation 査読

    Kohei Otsubo, H. Goto, M. Nishio, K. Kawamura, S. Yanagi, W. Nishie, T. Sasaki, T. Maehama, H. Nishina, Koshi Mimori, T. Nakano, H. Shimizu, T. W. Mak, K. Nakao, Yoichi Nakanishi, A. Suzuki

    Oncogene   36 ( 29 )   4201 - 4211   2017年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/onc.2017.58

  • Extraction of cell-free DNA from urine, using polylysine-coated silica particles 査読

    Sho Takano, Qingjiang Hu, Takaki Amamoto, Paulo Refinetti, Koshi Mimori, Takashi Funatsu, Masaru Kato

    Fresenius Zeitschrift fur Analytische Chemie   409 ( 16 )   4021 - 4025   2017年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00216-017-0345-3

  • DDR2 expression is associated with a high frequency of peritoneal dissemination and poor prognosis in colorectal cancer 査読

    Shin Sasaki, Masami Ueda, Tomohiro Iguchi, Manabu Kaneko, Hiroshi Nakayama, Toshiyuki Watanabe, Atsuhiko Sakamoto, Koshi Mimori

    Anticancer Research   37 ( 5 )   2587 - 2591   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/anticanres.11603

  • phyC Clustering cancer evolutionary trees 査読

    Yusuke Matsui, Atsushi Niida, Ryutaro Uchi, Koshi Mimori, Satoru Miyano, Teppei Shimamura

    PLoS Computational Biology   13 ( 5 )   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1371/journal.pcbi.1005509

  • Up-regulation of SLC9A9 promotes cancer progression and is involved in poor prognosis in colorectal cancer 査読

    Masami Ueda, Tomohiro Iguchi, Takaaki Masuda, Hisateru Komatsu, Sho Nambara, Shotaro Sakimura, Hidenari Hirata, Ryutaro Uchi, Hidetoshi Eguchi, Shuhei Ito, Keishi Sugimachi, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori, Koshi Mimori

    Anticancer Research   37 ( 5 )   2255 - 2263   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/anticanres.11562

  • Phosphoserine phosphatase is a novel prognostic biomarker on chromosome 7 in colorectal cancer 査読

    Kuniaki Sato, Takaaki Masuda, Qingjiang Hu, Taro Tobo, Shinya Kidogami, Yushi Ogawa, Tomoko Saito, Sho Nambara, Hisateru Komatsu, Hidenari Hirata, Shotaro Sakimura, Ryutaro Uchi, Naoki Hayashi, Tomohiro Iguchi, Hidetoshi Eguchi, Shuhei Ito, Takashi Nakagawa, Koshi Mimori

    Anticancer Research   37 ( 5 )   2365 - 2371   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/anticanres.11574

  • MicroRNA in various aspects of cancer development 査読

    Sho Nambara, Koshi Mimori

    Japanese Journal of Cancer and Chemotherapy   44 ( 5 )   362 - 366   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Attenuated RND1 Expression Confers Malignant Phenotype and Predicts Poor Prognosis in Hepatocellular Carcinoma. 査読 国際誌

    Ann Surg Oncol.   24 ( 3 )   850 - 859   2017年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-016-5573-9.

  • Attenuated RND1 Expression Confers Malignant Phenotype and Predicts Poor Prognosis in Hepatocellular Carcinoma 査読

    Hisateru Komatsu, Tomohiro Iguchi, Takaaki Masuda, Hidenari Hirata, Masami Ueda, Shinya Kidogami, Yushi Ogawa, Kuniaki Sato, Qingjiang Hu, Sho Nambara, Tomoko Saito, Shotaro Sakimura, Ryutaro Uchi, Shuhei Ito, Hidetoshi Eguchi, Keishi Sugimachi, Hidetoshi Eguchi, Yuichiro Doki, Masaki Mori, Koshi Mimori

    Annals of Surgical Oncology   24 ( 3 )   850 - 859   2017年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-016-5573-9

  • Clinical Significance of FANCD2 Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma. 査読 国際誌

    Anticancer Res.   37 ( 3 )   1083 - 1090   2017年3月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

  • Overexpression of CXCR7 Is a Novel Prognostic Indicator in Gastric Cancer. 査読 国際誌

    Dig Surg   2016年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1159/000452977

  • miR-146a Polymorphism (rs2910164) Predicts Colorectal Cancer Patients' Susceptibility to Liver Metastasis. 査読 国際誌

    PLoS One   11 ( 11 )   e0165912 - e0165912   2016年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1371/journal.pone.0165912

  • Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence. 査読 国際誌

    Oncotarget   7 ( 38 )   62280 - 62291   2016年9月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.18632/oncotarget.11409.

  • 8q24 Polymorphisms and Diabetes Mellitus Regulate Apolipoprotein A-IV in Colorectal Carcinogenesis 査読 国際誌

    Ann Surg Oncol.   23 ( 4 )   546- - 551   2016年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-016-5374-1

  • Increased Copy Number of the Gene Encoding SF3B4 Indicates Poor Prognosis in Hepatocellular Carcinoma. 査読 国際誌

    Anticancer Res.   36 ( 5 )   2139 - 2144   2016年6月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

  • Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma. 査読 国際誌

    Cancer Res   76 ( 11 )   3265 - 3276   2016年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1158/0008-5472.CAN-15-2601

  • Rapid diagnosis of lymph node metastasis in breast cancer using a new fluorescent method with γ-glutamyl hydroxymethyl rhodamine green 査読 国際誌

    9 ( 6 )   27525 - 27525   2016年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/srep27525.

  • HOXB7 Expression is a Novel Biomarker for Long-term Prognosis After Resection of Hepatocellular Carcinoma. 査読 国際誌

    Anticancer Res.   36 ( 6 )   2767 - 2773   2016年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Aberrant Methylation of FOXE1 Contributes to a Poor Prognosis for Patients with Colorectal Cancer. 招待 査読 国際誌

    Ann Surg Oncol   23 ( 12 )   3948 - 3955   2016年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-016-5289-x

  • Clinical and biological significance of transcription termination factor, RNA polymerase I in human liver hepatocellular carcinoma. 査読 国際誌

    Hisateru Komatsu, Iguchi Tomohiro, Masami Ueda, Sho Nanbara, Tomoko Saito, Hidenari Hirata, Shotaro Sakimura, Yuki Takano, Ryutaro Uchi, Shinden Yoshiaki, Hidetoshi Eguchi, Takaaki Masuda, Keishi Sugimachi, Hidetoshi Eguchi, Yuichiro Doki, Masaki Mori, Koshi Mimori

    Oncol Rep   35 ( 4 )   2073 - 2080   2016年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/or.2016.4593.

  • An Integrative Analysis to Identify Driver Genes in Esophageal Squamous Cell Carcinoma. 査読 国際誌

    Genta Sawada, Atsushi Niida, HIdenari Hirata, Hisateru Komatsu, Ryutaro Uchi, Teppei Shimamura, Yusuke Takahashi, Junji Kurashige, Tae Matsumura, Hiroki Ueo, Yuki Takano, Masami Ueda, Shotaro Sakimura, Shinden Yoshiaki, Hidetoshi Eguchi, Sudo Tomoya, Keishi Sugimachi, Koshi Mimori

    PLoS One.   10 ( 10 )   e0139808   2015年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1371/journal.pone.0139808.

  • Identification of Recurrence-Related microRNAs from Bone Marrow in Hepatocellular Carcinoma Patients. 査読 国際誌

    Keishi Sugimachi, Shotaro Sakimura, Akira Tomokuni, Ryutaro Uchi, Hidenari Hirata, Hisateru Komatsu, Shinden Yoshiaki, Iguchi Tomohiro, Hidetoshi Eguchi, Takaaki Masuda, Kazutoyo Morita, Ken Shirabe, Hidetoshi Eguchi, Yoshihiko Maehara, Masaki Mori, Koshi Mimori

    J Clin Med.   4 ( 8 )   1600 - 1611   2015年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3390/jcm4081600.

  • Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. 査読 国際誌

    Tae Matsumura, Keishi Sugimachi, Hisae Iinuma, Yusuke Takahashi, Junji Kurashige, Genta Sawada, Masami Ueda, Ryutaro Uchi, Hiroki Ueda, Yuki Takano, Shinden Yoshiaki, Hidetoshi Eguchi, Hirofumi Yamamoto, Yuichiro Doki, Takahiro Ochiya, Koshi Mimori

    Br J Cancer   113 ( 2 )   275 - 281   2015年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/bjc.2015.201.

  • miR-29b is an indicator of prognosis in breast cancer patients. 査読 国際誌

    Shinden Yoshiaki, Iguchi Tomohiro, Akiyoshi Sayuri, Hiroki Ueo, Masami Ueda, Hidenari Hirata, Shotaro Sakimura, Ryutaro Uchi, Yuki Takano, Hidetoshi Eguchi, Keishi Sugimachi, Yuko Kijima, Shoji Natsugoe, Koshi Mimori

    Mol Clin Oncol.   3 ( 4 )   919 - 923   2015年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/mco.2015.565

  • Overexpression of Transcription Termination Factor 1 is Associated with a Poor Prognosis in Patients with Colorectal Cancer. 査読 国際誌

    Masami Ueda, Iguchi Tomohiro, Sho Nanbara, Tomoko Saito, Hisateru Komatsu, Shotaro Sakimura, Hidenari Hirata, Ryutaro Uchi, Yuki Takano, Shinden Yoshiaki, Hidetoshi Eguchi, Takaaki Masuda, Keishi Sugimachi, Hirofumi Yamamoto, Yuichiro Doki, Koshi Mimori

    Ann Surg Oncol.   3   S1490. - S1498   2015年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-015-4652-7.

  • Rapid intraoperative visualization of breast lesions with γ-glutamyl hydroxymethyl rhodamine green. 招待 査読 国際誌

    13 ( 5 )   12080   2015年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/srep12080.

  • A long noncoding RNA, lncRNA-ATB, is involved in the progression and prognosis of colorectal cancer. 査読 国際誌

    Iguchi Tomohiro, Ryutaro Uchi, Sho Nanbara, Tomoko Saito, Hisateru Komatsu, Hidenatri Hitara, Masami Ueda, Shotaro Sakimura, Yuki Takano, Junji Kurashige, Shinden Yoshiaki, Hidetoshi Eguchi, Keishi Sugimachi, Yoshihiko Maehara, Koshi Mimori

    Anticancer Res.   35 ( 3 )   1385 - 1388   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric Cancer. 査読 国際誌

    2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND:

    A recent study reported that long non-coding RNA activated by TGF-β (lncRNA-ATB) induced epithelial-mesenchymal transition (EMT) through the transforming growth factor-β (TGF-β)/miR-200s/ZEB axis in hepatocellular carcinoma. Herein, we focused on the clinical significance of lncRNA-ATB in gastric cancer (GC) patients.
    MATERIALS AND METHODS:

    Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was performed to examine expression of lncRNA-ATB, miR-200b, and miR-200c in GC tissues (n = 183). Patients were divided into high and low lncRNA-ATB expression groups using a cutoff of lncRNA-ATB/GAPDH ≥0.60 or <0.60 to determine the clinicopathological significance of lncRNA-ATB in GC. Moreover, we evaluated the expression of TGF-β, lncRNA-ATB, miR-200s, and ZEB1 in GC cell lines by qRT-PCR. GC cell lines were treated by recombinant TGF-β1 or TGF-β receptor inhibitor to examine morphologic changes and genetic alterations, such as lncRNA-ATB, miR-200s, and ZEB1 levels, with respect to the EMT phenotype.
    RESULTS:

    The high lncRNA-ATB group experienced a lower overall survival rate compared with the low lncRNA-ATB group, and multivariate analysis indicated that lncRNA-ATB was an independent prognostic factor (hazard ratio 3.50; 95 % CI 1.73-7.44; p = 0.0004). miR-200c levels were lower and ZEB1 levels were higher in the high lncRNA-ATB group than in the low lncRNA-ATB group. Treatment with TGF-β in GC cell lines resulted in morphological EMT changes, upregulation of lncRNA-ATB and ZEB1, and downregulation of miR-200c and CDH1. SB431542 reduced lncRNA-ATB expression.
    CONCLUSION:

    LncRNA-ATB plays an important role in EMT to promote invasion and metastasis through the TGF-β/miR-200s/ZEB axis, resulting in a poor prognosis in GC. LncRNA-ATB is a novel biomarker of lncRNA, indicative of a poor prognosis in GC patients.

    DOI: 10.1245/s10434-015-4554-8

  • Significance of Polypyrimidine Tract-Binding Protein 1 Expression in Colorectal Cancer. 査読 国際誌

    Hidekazu Takahashi, Junichi Nishimura, Yoshinori Kagawa, Yoshihiro Kano, Yusuke Takahashi, Xin Wu, Masayuki Hiraki, Atsushi Hamabe, Masamitsu Konno, Naotsugu Haraguchi, Ichiro Takemasa, Tsunekazu Mizushima, Masaru Ishii, Koshi Mimori, Hideshi Ishii, Yuichiro Doki, Masaki Mori, Hirofumi Yamamoto

    Molecular Cancer Therapeutics   2015年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1158/1535-7163

  • F-box protein FBXW7 inhibits-cancer metastasis in a non-cell-autonomous manner 査読 国際誌

    JOURNAL OF CLINICAL INVESTIGATION   125 ( 2 )   2015年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1172/JCI78782

  • The miR-506-Induced Epithelial-Mesenchymal Transition is Involved in Poor Prognosis for Patients with Gastric Cancer. 査読 国際誌

    Shotaro Sakimura, Keishi Sugimachi, Junji Kurashige, Msasami Ueda, Hidenari Hirata, Sho Nanbara, Hisateru Komatsu, Tomoko Saito, Yuki Takano, Ryutaro Uchi, Etsuko Sakimura, Shinden Yoshiaki, Iguchi Tomohiro, Hidetoshi Eguchi, Yugo Oba, Sumio Hoka, Koshi Mimori

    Ann Surg Oncol.   2015年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-015-4418-2

  • Epigenetic modulation and repression of miR-200b by cancer-associated fibroblasts contribute to cancer invasion and peritoneal dissemination in gastric cancer 査読 国際誌

    Junji Kurasige, Koshuke Mima, Genta Sawada, Yusuke Takahashi, Hidetoshi Eguchi, Keishi Sugimachi, Masaki Mori, Kazuyoshi Yanagihara, Masakazu Yashiro, Kosei Hirakawa, Hideo Baba, Koshi Mimori

    CARCINOGENESIS   36 ( 1 )   133 - 141   2015年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/carcin/bgu232

  • Overexpression of Transcription Termination Factor 1 is Associated with a Poor Prognosis in Patients with Colorectal Cancer. 査読 国際誌

    Masami Ueda, Iguchi Tomohiro, Sho Nanbara, Tomoko Saito, Hisateru Komatsu, Shotaro Sakimura, Hidenari Hirata, Ryutaro Uchi, Yuki Takano, Shinden Yoshiaki, Hidetoshi Eguchi, Takaaki Masuda, Keishi Sugimachi, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori, Koshi Mimori

    Ann Surg Oncol.   2015年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-015-4652-7

  • Diminished Expression of MiR-15a Is an Independent Prognostic Marker for Breast Cancer Cases 査読 国際誌

    Shinden Yoshiaki, Akiyoshi Sayuri, Ueo Hiroki, Sho Nanbara, Tomoko Saito, Hisateru Komatsu, Masami Ueda, Hidenari Hirata, Shotaro Sakimura, Ryutaro Uchi, Yuki Takano, Iguchi Tomohiro, Hidetoshi Eguchi, Keishi Sugimachi, Y Kijima, Hiroaki Ueo, Shoji Natsugoe, Koshi Mimori

    ANTICANCER RESEARCH   35 ( 1 )   2015年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Epigenetic modulation and repression of miR-200b by cancer-associated fibroblasts contribute to cancer invasion and peritoneal dissemination in gastric cancer 査読 国際誌

    Junji Kurasige, Koshuke Mima, Genta Sawada, Yusuke Takahashi, Hidetoshi Eguchi, Keishi Sugimachi, Masaki Mori, Kazuyoshi Yanagihara, Masakazu Yashiro, Kosei Hirakawa, Hideo Baba, Koshi Mimori

    CARCINOGENESIS   36 ( 1 )   133 - 141   2015年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/carcin/bgu232

  • Loss of CDCP1 Expression Promotes Invasiveness and Poor Prognosis in Esophageal Squamous Cell Carcinoma 査読 国際誌

    Genta Sawada, Yusuke Takahashi, Atsushi Niida, Teppei Shimamura, Junji Kurashige, Tae Matsumura, Hiroki Ueo, Ryutaro Uchi, Yuki Takano, Masami Ueda, Hidernari Hirata, Shotaro Sakimura, Shinden Yoshiaki, Hidetoshi Eguchi, Sudo Tomoya, Keishi Sugimachi, Satoru Miyano, Yuichiro Doki, Masaki Mori, Koshi Mimori

    ANNALS OF SURGICAL ONCOLOGY   21   2014年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-014-3740-4

  • Clinical Significance of GAB2, a Scaffolding/Docking Protein Acting Downstream of EGFR in Human Colorectal Cancer 査読 国際誌

    Tae Matsumura, Keishi Sugimachi, Yusuke Takahashi, Ryutaro Uchi, Genta Sawada, Masami Ueda, Hidenari Hirata, Shotaro Sakimura, Hiroki Ueo, Yuki Takano, Junji Kurashige, Shinden Yoshiaki, Hidetoshi Eguchi, Sudo Tomoya, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori, Koshi Mimori

    ANNALS OF SURGICAL ONCOLOGY   21   S743 - S749   2014年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-014-3889-x

  • Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma. 査読 国際誌

    Hidenari Hirata, Keishi Sugimachi, Yusuke Takahashi, Masami Ueda, Shotaro Sakimura, Ryutaro Uchi, Junji Kurashige, Yuki Takano, Sho Nanbara, Hisateru Komatsu, Tomoko Saito, Shinden Yoshiaki, Iguchi Tomohiro, Hidetoshi Eguchi, Kazushige Atsumi, Katsumi Sakamoto, Toshio Doi, Masakazu Hirakawa, Hiroshi Honda, Koshi Mimori

    Ann Surg Oncol.   2014年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-014-4242-0

  • Prognostic Significance of High Mobility Group Box 1 (HMGB1) Expression in Patients with Colorectal Cancer 査読 国際誌

    Masami Ueda, Yusuke Takahashi, Shinden Yoshiaki, Shotaro Sakimura, Hidenari Hirata, Ryutaro Uchi, Yuki Takano, Junji Kurashige, Iguchi Tomohiro, Hidetoshi Eguchi, Keishi Sugimachi, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori, Koshi Mimori

    ANTICANCER RESEARCH   34 ( 10 )   5357 - 5362   2014年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition 査読 国際誌

    Atsushi Hamabe, Masamitsu Konno, Nobuhiro Tanuma, Hiroshi Shima, Kenta Tsunekuni, Koichi Kawamoto, Naohiro Nishida, Jun Koseki, Koshi Mimori, Noriko Gotoh, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori, Hideshi Ishii

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   111 ( 43 )   2014年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1073/pnas.1407717111

  • A single nucleotide polymorphism in fibronectin 1 determines tumor shape in colorectal cancer. 査読 国際誌

    Hiroyuki Kida, Yuki Takano, Ken Yamamoto, Masaki Mori, Katsuhiko Yanaga, Jun-Ichi Tanaka, Shin-Ei Kudo, Koshi Mimori

    Oncol Rep.   32 ( 2 )   548 - 552   2014年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/or.2014.3251

  • Aberrant Expression of Plastin-3 Via Copy Number Gain Induces the Epithelial-Mesenchymal Transition in Circulating Colorectal Cancer Cells.

    Koshi Mimori

    ANNALS OF SURGICAL ONCOLOGY   2014年1月

     詳細を見る

    記述言語:英語  

  • Up-regulation of NEK2 by MicroRNA-128 Methylation is Associated with Poor Prognosis in Colorectal Cancer

    Koshi Mimori

    ANNALS OF SURGICAL ONCOLOGY   21 ( 1 )   2014年1月

     詳細を見る

    記述言語:英語  

    DOI: 10.1245/s10434-013-3264-3

  • Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. 国際誌

    Koshi Mimori

    Br J Cancer. 2014 Jan 7;110(1):164-71. doi: 10.1038/bjc.2013.698. Epub 2013 Nov 5.   2014年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Contrasting Expression Patterns of Histone mRNA and microRNA 760 in Patients with Gastric Cancer

    Koshi Mimori

    CLINICAL CANCER RESEARCH   19 ( 23 )   2013年12月

     詳細を見る

    記述言語:英語  

    DOI: 10.1158/1078-0432.CCR-12-3186

  • Cell Cycle-Dependent Rho GTPase Activity Dynamically Regulates Cancer Cell Motility and Invasion In Vivo

    Koshi Mimori

    PLOS ONE   8 ( 12 )   2013年12月

     詳細を見る

    記述言語:英語  

    DOI: 10.1371/journal.pone.0083629

  • PICT1 regulates TP53 via RPL11 and is involved in gastric cancer progression

    Koshi Mimori

    BRITISH JOURNAL OF CANCER   109 ( 8 )   2013年10月

     詳細を見る

    記述言語:英語  

    DOI: 10.1038/bjc.2013.561

  • EGFR gets in the way of microRNA biogenesis

    Koshi Mimori

    CELL RESEARCH   23 ( 10 )   2013年10月

     詳細を見る

    記述言語:英語  

    DOI: 10.1038/cr.2013.87

  • CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer

    Koshi Mimori

    GENOME RESEARCH   23 ( 9 )   2013年9月

     詳細を見る

    記述言語:英語  

    DOI: 10.1101/gr.152942.112

  • Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway

    Iwaya Takeshi, Yokobori Takehiko, Nishida, Naohiro, Sudo Tomoya, Fumiaki Tanaka, Shibata Kohei, Sawada, Genta, Takahashi, Yusuke, Ishibashi, Masahisa, Wakabayashi, Go, Mori, Masaki, Koshi Mimori

    CARCINOGENESIS   33 ( 12 )   2391 - 2397   2012年12月

     詳細を見る

    記述言語:英語  

    DOI: 10.1093/carcin/bgs288

  • MicroRNA-10b is a Prognostic Indicator in Colorectal Cancer and Confers Resistance to the Chemotherapeutic Agent 5-Fluorouracil in Colorectal Cancer Cells

    Nishida, Naohiro, Yamashita, Shinya, Koshi Mimori, Sudo Tomoya, Fumiaki Tanaka, Shibata Kohei, Yamamoto, Hirofumi, Ishii, Hideshi, Doki, Yuichiro, Mori, Masaki

    ANNALS OF SURGICAL ONCOLOGY   19 ( 9 )   3065 - 3071   2012年9月

     詳細を見る

    記述言語:英語  

    DOI: 10.1245/s10434-012-2246-1

  • Increased Risk for CRC in Diabetic Patients with the Nonrisk Allele of SNPs at 8q24

    Ishimaru, Shinya, Koshi Mimori, Ken Yamamoto, Hiroshi Inoue, Imoto, Seiya, Shuichi; Yamaguchi, Rui; Sato, Sato Tetsuya, Toh, Hiroyuki, Iinuma, Hisae, Toyoki Maeda, Ishii, Hideshi, Suzuki, Sadao, Tokudome, Shinkan, Watanabe, Masahiko, Tanaka, Jun-ichi, Kudo, Shin-ei, Sugihara, Ken-ichi, Hase, Kazuo, Mochizuki, Hidetaka

    ANNALS OF SURGICAL ONCOLOGY   19 ( 9 )   2853 - 2858   2012年9月

     詳細を見る

    記述言語:英語  

    DOI: 10.1245/s10434-012-2278-6

  • Copy number loss of FBXW7 is related to gene expression and poor prognosis in esophageal squamous cell carcinoma

    Yokobori, Takehiko, Koshi Mimori, Iwatsuki, Masaaki, Ishii, Hideshi, Fumiaki Tanaka, Sato Tetsuya, Toh, Hiroyuki, Sudo Tomoya, Iwaya, Takeshi, Tanaka, Yoichi, Onoyama, Ichiro, Kuwano, Hiroyuki, Nakayama, Keiichi I., Mori, Masaki

    INTERNATIONAL JOURNAL OF ONCOLOGY   41 ( 1 )   253 - 259   2012年7月

     詳細を見る

    記述言語:英語  

    DOI: 10.3892/ijo.2012.1436

  • Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters. 査読 国際誌

    Nishida N, Nagahara M, Sato T, Mimori K, Sudo T, Tanaka F, Shibata K, Ishii H, Sugihara K, Doki Y, Mori M.

    Clin Cancer Res   18 ( 11 )   2012年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. 査読 国際誌

    Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, Miyano S, Mori M.

    Cancer Res   71 ( 20 )   2011年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Reprogramming of mouse and human cells to pluripotency using mature microRNAs. 査読 国際誌

    Miyoshi N, Ishii H, Nagano H, Haraguchi, Dewi DL, Kano Y Nishikawa S, Tanemura T, Mimori K, Tanaka F, Saito T, Nishimura J; Takemasa I, Mizusima T, Ikeda M, Yamamoto H, Sekimoto M, Doki Y, Mori M.

    Cell Stem Cell   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Clinical Significance of Circulating Tumor Cells Including Cancer Stem-like Cells in Peripheral Blood for Recurrence and Prognosis in Colorectal Cancer Patients with Dukes stage B and C. 招待 査読 国際誌

    Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M, Mori M.

    J Clin Oncol   29   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Reply to B Faltas et al. 査読 国際誌

    Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Nozawa K, Ishihara Matsuda KN, Fukushima R, Okinaga K, Sasako M, Mori M

    J Clin Oncol   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Clinical significance of miR-146a in gastric cancer cases. 査読 国際誌

    Kogo R , Mimori K, Tanaka F, Komune S, Mori M

    Clin Cancer Res   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Clinical significance of miR-146a in gastric cancer cases. 査読 国際誌

    Kogo R , Mimori K, Tanaka F, Komune S, Mori M

    Clin Cancer Res   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Serum Matrix-Metalloproteinase-1 is a Bona Fide Prognostic Marker for Colorectal Cancer. 査読 国際誌

    Mimori K*, Tahara K*, Iinuma H, Iwatsuki M, Yokobori T, Ishii H, Anai H, Kitano S,Mori M

    Ann Surg Oncol   17 ( 12 )   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Regulation of the MDM2-p53 Pathway and Tumor Growth by PICT1/GLTSCR2 via Nucleolar RPL11. 査読 国際誌

    Sasaki M, Kawahara K, Nishio M, Mimori K, Kogo R, Hamada K, Itoh B, Wangjia J, Komatsu Y, Yang YR, Hikasa H, Horie Y, Yamashita T, Kamijo T, Zhang Y, Prives C, Nakano T, Mak TW, Sasaki T, Maehama T, Mori M, Suzuki A.

    Nat Med   2011年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Identification of Recurrence-Related microRNAs in the Bone Marrow of Breast Cancer Patients. 査読 国際誌

    Mimori K*, Ota D*, Yokobori T, Iwatsuki M, Kataoka A, Masuda N, Ishii H, Ohno S,Mori S

    Int J Oncol   2010年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Preoperative u-PAR Gene Expression in Bone Marrow Indicates the Potential Power of Recurrence in Breast Cancer Cases. 国際誌

    Mimori K, Kataoka A, Yamaguchi H, Masuda N, Kosaka Y, Ishii H, Ohno S, Mori M.

    Ann Surg Oncol   2009年5月

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

  • Identification of the expression profile of apoptotic esophageal cancer cells by adenoviral-fragile histidine triad treatment.

    Mimori K, Ishii H, Inoue H, Barnard GF, Mori M.

    J Gastroenterol Hepatorol   2009年5月

  • Important matters to identify robust markers for metastasis and recurrence in solid cancer.

    Mimori K, Iwatsuki M, Yokobori T, Mori M.

    Ann Surg Oncol   2009年5月

  • Hematogenous Metastasis in Gastric Cancer Requires Isolated Tumor Cells and Expression of Vascular Endothelial Growth Factor Receptor-1

    Mimori K, Fukagawa T Kosaka Y, Kita Y, Ishikawa K, Etoh T, Iinuma H, Sasako M, Mori M

    Clin Cancer Res   2008年6月

  • Loss of MAL expression in precancerous lesions of the esophagus.

    Mimori K, Nishida K Nakamura Y, Ieta K, Yoshikawa Y, Sasaki A, Ishii H, Alonso MA, Mori M

    Ann Surg Oncol   2007年1月

  • Somatic mutations of epidermal growth factor receptor in colorectal carcinoma.

    Nagahara H, Mimori K, Ohta M, Utsunomiya T, Inoue H, Barnard GF, Ohira M, Hirakawa K, Mori M.

    Clin Cancer Res   11 ( 4 )   1368 - 1371   2005年1月

     詳細を見る

  • FHIT is up-regulated by inflammatory stimuli and inhibits prostaglandin E2-mediated cancer progression.

    Mimori K, Ishii H, Nagahara H, Sudo T, Yamashita K, Inoue H, Barnard GF, MoriM

    Cancer Res   66 ( 5 )   2683 - 2690   2005年1月

     詳細を見る

  • FHIT is up-regulated by inflammatory stimuli and inhibits prostaglandin E2-mediated cancer progression.

    Mimori K, Ishii H, Nagahara H, Sudo T, Yamashita K, Inoue H, Barnard GF, MoriM

    Cancer Res   66 ( 5 )   2683 - 2690   2005年1月

     詳細を見る

  • Coexpression of MMP-7 and EGF receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells

    Mimori K

    Clin Cancer Res   10 ( 24 )   8243 - 8249   2004年12月

     詳細を見る

    記述言語:英語  

    DOI: 10.1158/1078-0432.CCR-04-0849

  • MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway

    Mimori K, Shiraishi T, Mashino K, Sonoda H, Yamashita K, Yoshinaga K, Masuda T, Utsunomiya T, Alonso MA, Inoue H, Mori M.

    Oncogene   22 ( 22 )   3463 - 3471   2003年1月

     詳細を見る

  • A polymorphic change at codon 299 and splicing isoforms of SMARB1 gene in human solid carcinomas.

    Mimori K, Inoue H, Ueo H, Tanaka Y, Mori M

    Genomics   2002年1月

  • Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma.

    Mimori K*, Mori M*, Masuda T, Yoshinaga K, Yamashita K, Matsuyama A, Inoue H. (*equal contribution)

    Cancer Res   61 ( 20 )   7379 - 7382   2001年3月

  • Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit.

    Shiraishi T, Druck T, Mimori K, Flomenberg J, Berk L, Alder H, Miller W, Huebner K, Croce CM

    Proc Natl Acad Sci U S A.   2001年2月

  • Effect of adenoviral trancduction of FHIT into esophageal cancer cells.

    Ishii H, Dumon K, Vacchione A, Trapasso F, Mimori K, Alder H, Mori M, Sozzi G, Baffa R, Huebner K, Croce CM.

    Cancer Res   2001年1月

  • Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus.

    Mori M,Mimori K, Shiraishi T, Alder H, Inoue H, Tanaka Y, Sugimachi K, Huebner K, Croce CM.

    Cancer Res   60 ( 5 )   1177 - 1182   2000年1月

  • Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas.

    Mori M, Mimori K, Ueo H, Tsuji K, Shiraishi T, Barnard GF, Sugimachi K, Akiyoshi T

    J Clin Oncol   16 ( 1 )   128 - 132   1997年1月

  • p27 expression and gastric carcinoma. 査読

    Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T.

    Nat Med   3 ( 6 )   593 - 593   1997年1月

     詳細を見る

  • Elongation factor 1 gamma mRNA expression in oesophageal carcinoma. 国際誌

    Mimori K, Mori M, Inoue H, Ueo H, Mafune K, Akiyoshi T and Sugimachi K

    Gut   38 ( 1 )   66 - 70   1996年10月

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    DOI: 10.1136/gut.38.1.66

  • Elongation factor 1gamma mRNA expression in oesophageal carcinoma

    Mimori K, Mori M, Inoue H, Mafune K, Tanaka Y, Takubo T, Ueo H, Akiyoshi T, Sugimachi K.

    Gut   1996年1月

  • Detection of cancer micrometastasis in lymph nodes by the reverse transcriptase-polymerase chain reaction.

    Mori M, Mimori K, Inoue H, Barnard GF, Tsuji K, Nanbara S, Ueo H, Akiyoshi T.

    Cancer Res   55 ( 15 )   3417 - 3420   1995年11月

▼全件表示

書籍等出版物

  • Liquid Biopsy Using Cell-Free Tumor DNA for Gastrointestinal Cancers

    Nakano T., Abe T., Takao S., Saito H., Masuda T., Mimori K.

    Cancer Metastasis Through the Lymphovascular System  2022年1月    ISBN:9783030930844, 9783030930837

     詳細を見る

    Since the advent of precision medicine in 2015, personalized genomic profiles of mutated DNA from tumor tissues have been applied for the selection of compatible drugs for the clinical treatment of genomic aberrations. As a more convenient and less invasive method of precision medicine, liquid biopsy that analyzes mutated cell-free tumor DNA (ctDNA) can be used as a biomarker for postoperative recurrence of genomic aberrations and their appropriate treatment. In this chapter, we explore liquid biopsies for gastrointestinal (GI) cancers in detail. We review the literature on ctDNA-related issues, including the mechanism of ctDNA identification in plasma, the methodology for identifying ctDNA in profiles and targeted sequencing assays, intratumor heterogeneity, recent technological innovations in ctDNA analysis in GI cancers, and the limitations of current approaches. We also describe the clinical aspects of GI cancer, such as actionable targets and clinical trials using mutated ctDNA analysis, the significance of longitudinal observation of ctDNA for clonal evolution after targeted therapy, and the detection of minimal residual disease by ctDNA analysis. Finally, we summarize a few recent studies on ctDNA in colorectal, gastric, and esophageal cancers. (192)

    DOI: 10.1007/978-3-030-93084-4_13

    Scopus

講演・口頭発表等